CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: piroxicam
Accession: CHEBI:8249
browse the term
Definition: A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide with the exocyclic nitrogen of 2-aminopyridine. A non-steroidal anti-inflammatory drug of the oxicam class, it is used to relieve pain and works by preventing the production of endogenous prostaglandins involved in the mediation of pain, stiffness, tenderness and swelling.
Synonyms: exact_synonym: 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
related_synonym: 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid; FELDENE; Formula=C15H13N3O4S; InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20); InChIKey=QYSPLQLAKJAUJT-UHFFFAOYSA-N; Pyroxycam; SMILES=CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O; piroxicamum
xref: CAS:36322-90-4; DrugBank:DB00554; Drug_Central:2210; HMDB:HMDB0014694; KEGG:C01608; KEGG:D00127
xref_mesh: MESH:D010894
xref: PMID:11142413; PMID:12154043; PMID:28166217; Patent:DE1943265; Patent:US3591584; Reaxys:627692; Wikipedia:Piroxicam
G
Aars1
alanyl-tRNA synthetase 1
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of AARS1 mRNA]
CTD
PMID:21858171
NCBI chr19:38,999,130...39,021,152
Ensembl chr19:38,999,163...39,021,147
G
Abcd3
ATP binding cassette subfamily D member 3
decreases expression
ISO
Piroxicam results in decreased expression of ABCD3 mRNA
CTD
PMID:21858171
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
G
Acadvl
acyl-CoA dehydrogenase, very long chain
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of ACADVL mRNA
CTD
PMID:21858171
NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
G
Ackr3
atypical chemokine receptor 3
decreases expression
ISO
Piroxicam results in decreased expression of ACKR3 mRNA
CTD
PMID:19192274
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
G
Adipor2
adiponectin receptor 2
decreases expression
ISO
Piroxicam results in decreased expression of ADIPOR2 mRNA
CTD
PMID:21858171
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
G
Adm
adrenomedullin
increases expression
ISO
Piroxicam results in increased expression of ADM mRNA
CTD
PMID:21858171
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
G
Adora2a
adenosine A2a receptor
decreases expression
ISO
Piroxicam results in decreased expression of ADORA2A mRNA
CTD
PMID:19192274
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
G
Agfg1
ArfGAP with FG repeats 1
decreases expression
ISO
Piroxicam results in decreased expression of AGFG1 mRNA
CTD
PMID:21858171
NCBI chr 9:84,124,845...84,182,615
Ensembl chr 9:84,125,120...84,178,128
G
Aimp1
aminoacyl tRNA synthetase complex-interacting multifunctional protein 1
decreases expression
ISO
Piroxicam results in decreased expression of AIMP1 mRNA
CTD
PMID:21858171
NCBI chr 2:221,151,907...221,175,458
Ensembl chr 2:221,151,904...221,175,728
G
Ak2
adenylate kinase 2
increases expression
ISO
Piroxicam results in increased expression of AK2 mRNA
CTD
PMID:21858171
NCBI chr 5:141,308,650...141,364,633
Ensembl chr 5:141,346,063...141,364,632
G
Akap12
A-kinase anchoring protein 12
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of AKAP12 mRNA]
CTD
PMID:21858171
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
G
Akr7a2
aldo-keto reductase family 7, member A2
decreases expression
ISO
Piroxicam results in decreased expression of AKR7A2 mRNA
CTD
PMID:21858171
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
G
Aldh1a3
aldehyde dehydrogenase 1 family, member A3
decreases expression
ISO
Piroxicam results in decreased expression of ALDH1A3 mRNA
CTD
PMID:21858171
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
G
Amigo2
adhesion molecule with Ig like domain 2
decreases expression
ISO
Piroxicam results in decreased expression of AMIGO2 mRNA
CTD
PMID:19192274
NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695
G
Anp32a
acidic nuclear phosphoprotein 32 family member A
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of ANP32A mRNA Cisplatin promotes the reaction [Piroxicam results in decreased expression of ANP32A mRNA]
CTD
PMID:21858171
NCBI chr 8:62,829,099...62,865,443
Ensembl chr 8:62,827,456...62,865,443
G
Anxa10
annexin A10
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of ANXA10 mRNA
CTD
PMID:21858171
NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648
G
Aplp2
amyloid beta precursor like protein 2
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of APLP2 mRNA]
CTD
PMID:21858171
NCBI chr 8:29,599,230...29,662,311
Ensembl chr 8:29,599,230...29,661,855
G
Arc
activity-regulated cytoskeleton-associated protein
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of ARC mRNA
CTD
PMID:21858171
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
G
Arhgef2
Rho/Rac guanine nucleotide exchange factor 2
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of ARHGEF2 mRNA]
CTD
PMID:21858171
NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355
G
Arl6ip5
ARF like GTPase 6 interacting protein 5
increases expression
ISO
Piroxicam results in increased expression of ARL6IP5 mRNA
CTD
PMID:21858171
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
G
Asf1a
anti-silencing function 1A histone chaperone
decreases expression
ISO
Piroxicam results in decreased expression of ASF1A mRNA
CTD
PMID:21858171
NCBI chr20:32,893,962...32,908,808
Ensembl chr20:32,893,573...32,908,808
G
Asns
asparagine synthetase (glutamine-hydrolyzing)
increases expression
ISO
Piroxicam results in increased expression of ASNS mRNA
CTD
PMID:21858171
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
G
Aspm
assembly factor for spindle microtubules
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of ASPM mRNA]
CTD
PMID:21858171
NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755
G
Atad2
ATPase family, AAA domain containing 2
decreases expression
ISO
Piroxicam results in decreased expression of ATAD2 mRNA
CTD
PMID:21858171
NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738
G
Atf3
activating transcription factor 3
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of ATF3 mRNA Cisplatin inhibits the reaction [Piroxicam results in decreased expression of ATF3 mRNA]
CTD
PMID:21858171
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
G
Atf4
activating transcription factor 4
decreases expression
ISO
Piroxicam results in decreased expression of ATF4 mRNA
CTD
PMID:21858171
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
G
Atp1b1
ATPase Na+/K+ transporting subunit beta 1
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of ATP1B1 mRNA]
CTD
PMID:21858171
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
G
Atp2a2
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2
decreases expression
ISO
Piroxicam results in decreased expression of ATP2A2 mRNA
CTD
PMID:21858171
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
G
Atp5mc1
ATP synthase membrane subunit c locus 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of ATP5MC1 mRNA
CTD
PMID:21858171
NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124 Ensembl chr10:81,023,925...81,027,124
G
Atp6v1d
ATPase H+ transporting V1 subunit D
decreases expression
ISO
Piroxicam results in decreased expression of ATP6V1D mRNA
CTD
PMID:21858171
NCBI chr 6:97,656,725...97,672,295
Ensembl chr 6:97,656,576...97,672,303
G
Aurka
aurora kinase A
decreases expression
ISO
Piroxicam results in decreased expression of AURKA mRNA
CTD
PMID:21858171
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
G
Avpi1
arginine vasopressin-induced 1
multiple interactions
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of AVPI1 mRNA]
CTD
PMID:21858171
NCBI chr 1:240,930,236...240,936,154
Ensembl chr 1:240,930,236...240,936,154
G
Bag5
BAG cochaperone 5
decreases expression
ISO
Piroxicam results in decreased expression of BAG5 mRNA
CTD
PMID:21858171
NCBI chr 6:130,768,467...130,772,122
Ensembl chr 6:130,768,141...130,772,970
G
Bag6
BAG cochaperone 6
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of BAG6 mRNA
CTD
PMID:21858171
NCBI chr20:3,675,938...3,690,414
Ensembl chr20:3,675,938...3,688,657
G
Bard1
BRCA1 associated RING domain 1
decreases expression
ISO
Piroxicam results in decreased expression of BARD1 mRNA
CTD
PMID:21858171
NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
G
Baz1a
bromodomain adjacent to zinc finger domain, 1A
decreases expression
ISO
Piroxicam results in decreased expression of BAZ1A mRNA
CTD
PMID:21858171
NCBI chr 6:72,389,701...72,512,516
Ensembl chr 6:72,389,703...72,512,459
G
Bcar3
BCAR3 adaptor protein, NSP family member
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of BCAR3 mRNA Cisplatin affects the reaction [Piroxicam results in decreased expression of BCAR3 mRNA]
CTD
PMID:21858171
NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798
G
Bccip
BRCA2 and CDKN1A interacting protein
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of BCCIP mRNA]
CTD
PMID:21858171
NCBI chr 1:188,512,544...188,524,957
Ensembl chr 1:188,512,367...188,524,958
G
Bcl2a1
BCL2-related protein A1
decreases expression
ISO
Piroxicam results in decreased expression of BCL2A1 mRNA
CTD
PMID:19192274
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
G
Bclaf1
BCL2-associated transcription factor 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of BCLAF1 mRNA
CTD
PMID:21858171
NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:15,070,894...15,148,832
G
Birc5
baculoviral IAP repeat-containing 5
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of BIRC5 mRNA]
CTD
PMID:21858171
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
G
Bmp2k
BMP-2 inducible kinase
increases expression
ISO
Piroxicam results in increased expression of BMP2K mRNA
CTD
PMID:21858171
NCBI chr14:12,481,194...12,579,411
Ensembl chr14:12,484,729...12,579,134
G
Brcc3
BRCA1/BRCA2-containing complex subunit 3
decreases expression
ISO
Piroxicam results in decreased expression of BRCC3 mRNA
CTD
PMID:21858171
NCBI chr 9:1,986,942...1,989,484
Ensembl chr 9:1,986,575...1,991,080
G
Brms1
BRMS1, transcriptional repressor and anoikis regulator
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of BRMS1 mRNA
CTD
PMID:21858171
NCBI chr 1:202,345,766...202,355,028
Ensembl chr 1:202,345,704...202,355,028
G
Bst2
bone marrow stromal cell antigen 2
decreases expression
ISO
Piroxicam results in decreased expression of BST2 mRNA
CTD
PMID:19192274
NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979
G
Btg1
BTG anti-proliferation factor 1
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of BTG1 mRNA]
CTD
PMID:21858171
NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649
G
Bub1
BUB1 mitotic checkpoint serine/threonine kinase
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of BUB1 mRNA
CTD
PMID:21858171
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
G
Bub1b
BUB1 mitotic checkpoint serine/threonine kinase B
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of BUB1B mRNA]
CTD
PMID:21858171
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
G
C1d
C1D nuclear receptor corepressor
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of C1D mRNA
CTD
PMID:21858171
NCBI chr14:91,660,951...91,673,177
Ensembl chr14:91,660,989...91,672,852
G
Cacybp
calcyclin binding protein
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of CACYBP mRNA]
CTD
PMID:21858171
NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177
G
Cad
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of CAD mRNA
CTD
PMID:21858171
NCBI chr 6:25,292,133...25,315,078
Ensembl chr 6:25,292,133...25,319,861
G
Cadm1
cell adhesion molecule 1
decreases expression
ISO
Piroxicam results in decreased expression of CADM1 mRNA
CTD
PMID:21858171
NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833
G
Calm1
calmodulin 1
decreases expression
ISO
Piroxicam results in decreased expression of CALM1 mRNA
CTD
PMID:21858171
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
G
Cand1
cullin-associated and neddylation-dissociated 1
increases expression
ISO
Piroxicam results in increased expression of CAND1 mRNA
CTD
PMID:21858171
NCBI chr 7:54,681,114...54,719,002
Ensembl chr 7:54,680,900...54,718,993
G
Canx
calnexin
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of CANX mRNA
CTD
PMID:21858171
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
G
Capg
capping actin protein, gelsolin like
decreases expression
ISO
Piroxicam results in decreased expression of CAPG mRNA
CTD
PMID:21858171
NCBI chr 4:104,594,743...104,611,856
Ensembl chr 4:104,594,753...104,611,856
G
Capn7
calpain 7
decreases expression
ISO
Piroxicam results in decreased expression of CAPN7 mRNA
CTD
PMID:21858171
NCBI chr16:6,545,630...6,581,908
Ensembl chr16:6,545,731...6,581,905
G
Capza2
capping actin protein of muscle Z-line subunit alpha 2
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of CAPZA2 mRNA]
CTD
PMID:21858171
NCBI chr 4:45,978,142...46,014,032
Ensembl chr 4:45,977,807...46,013,864
G
Cast
calpastatin
increases expression
ISO
Piroxicam results in increased expression of CAST mRNA
CTD
PMID:21858171
NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659
G
Cav1
caveolin 1
decreases expression
ISO
Piroxicam results in decreased expression of CAV1 mRNA
CTD
PMID:21858171
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
G
Ccdc85b
coiled-coil domain containing 85B
increases expression
ISO
Piroxicam results in increased expression of CCDC85B mRNA
CTD
PMID:21858171
NCBI chr 1:202,763,645...202,764,660
Ensembl chr 1:202,763,631...202,764,703
G
Ccl20
C-C motif chemokine ligand 20
decreases expression
ISO
Piroxicam results in decreased expression of CCL20 mRNA; Piroxicam results in decreased expression of CCL20 protein
CTD
PMID:19192274
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
G
Ccn1
cellular communication network factor 1
increases expression
ISO
Piroxicam results in increased expression of CCN1 mRNA
CTD
PMID:19192274
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
G
Ccn2
cellular communication network factor 2
decreases expression
ISO
Piroxicam results in decreased expression of CCN2 mRNA
CTD
PMID:21858171
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
G
Ccn5
cellular communication network factor 5
increases expression
ISO
Piroxicam results in increased expression of CCN5 mRNA
CTD
PMID:19192274
NCBI chr 3:152,491,247...152,502,639
Ensembl chr 3:152,491,220...152,502,636
G
Ccna2
cyclin A2
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of CCNA2 mRNA]
CTD
PMID:21858171
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
G
Ccnb1
cyclin B1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of CCNB1 mRNA
CTD
PMID:21858171
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
G
Ccnb2
cyclin B2
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of CCNB2 mRNA]
CTD
PMID:21858171
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
G
Ccnc
cyclin C
decreases expression
ISO
Piroxicam results in decreased expression of CCNC mRNA
CTD
PMID:21858171
NCBI chr 5:35,266,828...35,284,943
Ensembl chr 5:35,266,823...35,296,584
G
Ccnd1
cyclin D1
increases expression
ISO
Piroxicam results in increased expression of CCND1 mRNA
CTD
PMID:21858171
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
G
Ccnd3
cyclin D3
decreases expression
ISO
Piroxicam results in decreased expression of CCND3 mRNA
CTD
PMID:21858171
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
G
Cd44
CD44 molecule
increases expression
ISO
Piroxicam results in increased expression of CD44 mRNA
CTD
PMID:21858171
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
G
Cd55
CD55 molecule (Cromer blood group)
increases expression
ISO
Piroxicam results in increased expression of CD55 mRNA
CTD
PMID:21858171
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
G
Cdc25a
cell division cycle 25A
decreases expression
ISO
Piroxicam results in decreased expression of CDC25A mRNA
CTD
PMID:21858171
NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
G
Cdc42
cell division cycle 42
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of CDC42 mRNA
CTD
PMID:21858171
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
G
Cdc45
cell division cycle 45
decreases expression
ISO
Piroxicam results in decreased expression of CDC45 mRNA
CTD
PMID:21858171
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
G
Cdc6
cell division cycle 6
increases expression
ISO
Piroxicam results in increased expression of CDC6 mRNA
CTD
PMID:21858171
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
G
Cdca3
cell division cycle associated 3
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of CDCA3 mRNA]
CTD
PMID:21858171
NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799
G
Cdca4
cell division cycle associated 4
increases expression
ISO
Piroxicam results in increased expression of CDCA4 mRNA
CTD
PMID:21858171
NCBI chr 6:131,892,305...131,901,571
Ensembl chr 6:131,892,087...131,901,564
G
Cdca8
cell division cycle associated 8
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of CDCA8 mRNA]
CTD
PMID:21858171
NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
G
Cdk1
cyclin-dependent kinase 1
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of CDK1 mRNA]
CTD
PMID:21858171
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
G
Cdk2
cyclin dependent kinase 2
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of CDK2 mRNA]
CTD
PMID:21858171
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
G
Cdkn1a
cyclin-dependent kinase inhibitor 1A
multiple interactions affects localization
ISO
[Cisplatin co-treated with Piroxicam] affects the localization of CDKN1A protein; [Cisplatin co-treated with Piroxicam] results in decreased expression of CDKN1A protein; [Piroxicam co-treated with Cisplatin] results in increased expression of CDKN1A mRNA; CDKN1A results in increased susceptibility to [Cisplatin co-treated with Piroxicam] Piroxicam affects the localization of CDKN1A protein
CTD
PMID:21858171
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
G
Cdkn1b
cyclin-dependent kinase inhibitor 1B
multiple interactions
EXP
Piroxicam inhibits the reaction [Azoxymethane results in decreased expression of CDKN1B protein]
CTD
PMID:12189186
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
G
Cdkn2a
cyclin-dependent kinase inhibitor 2A
multiple interactions
EXP
Piroxicam inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]; Piroxicam inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A protein]
CTD
PMID:12189186
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
G
Cdkn3
cyclin-dependent kinase inhibitor 3
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of CDKN3 mRNA
CTD
PMID:21858171
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
G
Cebpb
CCAAT/enhancer binding protein beta
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in increased expression of CEBPB mRNA] Piroxicam results in decreased expression of CEBPB mRNA
CTD
PMID:21858171
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
G
Cebpg
CCAAT/enhancer binding protein gamma
multiple interactions increases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of CEBPG mRNA] Piroxicam results in increased expression of CEBPG mRNA
CTD
PMID:21858171
NCBI chr 1:87,683,060...87,692,772
Ensembl chr 1:87,684,019...87,694,569
G
Cenpa
centromere protein A
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of CENPA mRNA
CTD
PMID:21858171
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
G
Cenpe
centromere protein E
decreases expression
ISO
Piroxicam results in decreased expression of CENPE mRNA
CTD
PMID:21858171
NCBI chr 2:223,637,035...223,695,692
Ensembl chr 2:223,636,998...223,695,669
G
Cep170
centrosomal protein 170
increases expression
ISO
Piroxicam results in increased expression of CEP170 mRNA
CTD
PMID:21858171
NCBI chr13:88,669,672...88,754,011
Ensembl chr13:88,670,358...88,732,226
G
Cep55
centrosomal protein 55
decreases expression
ISO
Piroxicam results in decreased expression of CEP55 mRNA
CTD
PMID:21858171
NCBI chr 1:235,832,823...235,848,401
Ensembl chr 1:235,832,878...235,848,394
G
Ces2h
carboxylesterase 2H
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of CES2 mRNA
CTD
PMID:21858171
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
G
Ciz1
CDKN1A interacting zinc finger protein 1
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of CIZ1 mRNA]
CTD
PMID:21858171
NCBI chr 3:15,658,479...15,673,762
Ensembl chr 3:15,658,539...15,673,762
G
Cks2
CDC28 protein kinase regulatory subunit 2
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of CKS2 mRNA]
CTD
PMID:21858171
NCBI chr17:13,570,611...13,575,770
G
Clcn3
chloride voltage-gated channel 3
decreases expression
ISO
Piroxicam results in decreased expression of CLCN3 mRNA
CTD
PMID:21858171
NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
G
Clgn
calmegin
decreases expression
ISO
Piroxicam results in decreased expression of CLGN mRNA
CTD
PMID:19192274
NCBI chr19:24,695,140...24,728,542
Ensembl chr19:24,696,875...24,728,758
G
Cnn3
calponin 3
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of CNN3 mRNA]
CTD
PMID:21858171
NCBI chr 2:209,518,948...209,550,107
Ensembl chr 2:209,518,948...209,550,104
G
Col1a1
collagen type I alpha 1 chain
increases expression
ISO
Piroxicam results in increased expression of COL1A1 mRNA
CTD
PMID:19192274
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
G
Colec12
collectin sub-family member 12
increases expression
ISO
Piroxicam results in increased expression of COLEC12 mRNA
CTD
PMID:19192274
NCBI chr18:732,950...920,620
Ensembl chr18:732,950...920,618
G
Cops3
COP9 signalosome subunit 3
decreases expression
ISO
Piroxicam results in decreased expression of COPS3 mRNA
CTD
PMID:21858171
NCBI chr10:44,618,115...44,652,807
Ensembl chr10:44,618,115...44,641,597
G
Coq8a
coenzyme Q8A
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of COQ8A mRNA]
CTD
PMID:21858171
NCBI chr13:91,904,731...91,933,588
Ensembl chr13:91,904,739...91,931,431
G
Cpsf1
cleavage and polyadenylation specific factor 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of CPSF1 mRNA
CTD
PMID:21858171
NCBI chr 7:108,319,429...108,330,018
Ensembl chr 7:108,319,434...108,329,934
G
Cpsf6
cleavage and polyadenylation specific factor 6
decreases expression
ISO
Piroxicam results in decreased expression of CPSF6 mRNA
CTD
PMID:21858171
NCBI chr 7:52,956,589...53,001,783
Ensembl chr 7:52,956,589...52,988,122
G
Crk
CRK proto-oncogene, adaptor protein
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of CRK mRNA
CTD
PMID:21858171
NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406
G
Crtc3
CREB regulated transcription coactivator 3
increases expression
ISO
Piroxicam results in increased expression of CRTC3 mRNA
CTD
PMID:21858171
NCBI chr 1:134,552,830...134,655,929
Ensembl chr 1:134,554,696...134,655,500
G
Csnk1a1
casein kinase 1, alpha 1
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of CSNK1A1 mRNA]
CTD
PMID:21858171
NCBI chr18:55,017,049...55,050,184
Ensembl chr18:55,017,055...55,049,271
G
Csnk2a2
casein kinase 2 alpha 2
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of CSNK2A2 mRNA
CTD
PMID:21858171
NCBI chr19:9,556,443...9,596,080
Ensembl chr19:9,556,260...9,596,080
G
Ctnnal1
catenin alpha-like 1
decreases expression
ISO
Piroxicam results in decreased expression of CTNNAL1 mRNA
CTD
PMID:21858171
NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431
G
Ctsc
cathepsin C
decreases expression
ISO
Piroxicam results in decreased expression of CTSC mRNA
CTD
PMID:21858171
NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387
G
Cul4b
cullin 4B
decreases expression
ISO
Piroxicam results in decreased expression of CUL4B mRNA
CTD
PMID:21858171
NCBI chr X:117,287,481...117,326,688
Ensembl chr X:117,287,484...117,326,688
G
Cxcl1
C-X-C motif chemokine ligand 1
decreases expression
ISO
Piroxicam results in decreased expression of CXCL1 mRNA
CTD
PMID:19192274
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
G
Cxcl2
C-X-C motif chemokine ligand 2
increases expression decreases expression
ISO
Piroxicam results in increased expression of CXCL2 mRNA Piroxicam results in decreased expression of CXCL2 mRNA
CTD
PMID:19192274 PMID:21858171
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
G
Cxcl3
C-X-C motif chemokine ligand 3
decreases expression
ISO
Piroxicam results in decreased expression of CXCL1 mRNA
CTD
PMID:19192274
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
G
Cxcr4
C-X-C motif chemokine receptor 4
decreases expression
ISO
Piroxicam results in decreased expression of CXCR4 mRNA
CTD
PMID:19192274
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
G
Cyb5b
cytochrome b5 type B
decreases expression
ISO
Piroxicam results in decreased expression of CYB5B mRNA
CTD
PMID:21858171
NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249
G
Cyfip2
cytoplasmic FMR1 interacting protein 2
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of CYFIP2 mRNA
CTD
PMID:21858171
NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113
G
Cyp19a1
cytochrome P450, family 19, subfamily a, polypeptide 1
multiple interactions decreases expression decreases activity
ISO
Piroxicam inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP19A1 mRNA] Piroxicam results in decreased expression of CYP19A1 mRNA Piroxicam results in decreased activity of CYP19A1 protein
CTD
PMID:15964185 PMID:19147701
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
G
Dbf4
DBF4-CDC7 kinase regulatory subunit
increases expression multiple interactions
ISO
Piroxicam results in increased expression of DBF4 mRNA Cisplatin inhibits the reaction [Piroxicam results in increased expression of DBF4 mRNA]
CTD
PMID:21858171
NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066
G
Dcxr
dicarbonyl and L-xylulose reductase
decreases expression
ISO
Piroxicam results in decreased expression of DCXR mRNA
CTD
PMID:21858171
NCBI chr10:106,006,404...106,008,293
G
Ddb2
damage specific DNA binding protein 2
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of DDB2 mRNA
CTD
PMID:21858171
NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631
G
Ddit3
DNA-damage inducible transcript 3
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of DDIT3 mRNA]
CTD
PMID:21858171
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
G
Ddx19a
DEAD-box helicase 19A
decreases expression
ISO
Piroxicam results in decreased expression of DDX19A mRNA
CTD
PMID:21858171
NCBI chr19:38,942,497...38,962,853
Ensembl chr19:38,942,496...38,962,854
G
Ddx39a
DExD-box helicase 39A
decreases expression
ISO
Piroxicam results in decreased expression of DDX39A mRNA
CTD
PMID:21858171
NCBI chr19:24,418,743...24,427,422
Ensembl chr19:24,418,114...24,426,954
G
Ddx3x
DEAD-box helicase 3, X-linked
decreases expression
ISO
Piroxicam results in decreased expression of DDX3X mRNA
CTD
PMID:21858171
NCBI chr X:9,479,532...9,493,169
Ensembl chr X:9,479,532...9,493,168
G
Degs1
delta(4)-desaturase, sphingolipid 1
increases expression
ISO
Piroxicam results in increased expression of DEGS1 mRNA
CTD
PMID:21858171
NCBI chr13:93,946,154...93,953,677
Ensembl chr13:93,946,157...93,953,664
G
Dffa
DNA fragmentation factor subunit alpha
decreases expression
ISO
Piroxicam results in decreased expression of DFFA mRNA
CTD
PMID:21858171
NCBI chr 5:159,540,715...159,553,639
Ensembl chr 5:159,540,715...159,553,633
G
Dhfr
dihydrofolate reductase
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of DHFR mRNA Cisplatin promotes the reaction [Piroxicam results in decreased expression of DHFR mRNA]
CTD
PMID:21858171
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
G
Dhx9
DExH-box helicase 9
decreases expression
ISO
Piroxicam results in decreased expression of DHX9 mRNA
CTD
PMID:21858171
NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069
G
Diaph1
diaphanous-related formin 1
decreases expression
ISO
Piroxicam results in decreased expression of DIAPH1 mRNA
CTD
PMID:21858171
NCBI chr18:29,669,659...29,769,070
Ensembl chr18:29,669,659...29,769,172
G
Dlgap5
DLG associated protein 5
increases expression multiple interactions
ISO
Piroxicam results in increased expression of DLGAP5 mRNA Cisplatin inhibits the reaction [Piroxicam results in increased expression of DLGAP5 mRNA]
CTD
PMID:21858171
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
G
Dnaja1
DnaJ heat shock protein family (Hsp40) member A1
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of DNAJA1 mRNA Cisplatin affects the reaction [Piroxicam results in decreased expression of DNAJA1 mRNA]
CTD
PMID:21858171
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
G
Dnajb1
DnaJ heat shock protein family (Hsp40) member B1
decreases expression
ISO
Piroxicam results in decreased expression of DNAJB1 mRNA
CTD
PMID:21858171
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
G
Dnajb12
DnaJ heat shock protein family (Hsp40) member B12
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of DNAJB12 mRNA
CTD
PMID:21858171
NCBI chr20:27,828,216...27,846,428
Ensembl chr20:27,828,235...27,846,427
G
Dnajb6
DnaJ heat shock protein family (Hsp40) member B6
decreases expression
ISO
Piroxicam results in decreased expression of DNAJB6 mRNA
CTD
PMID:21858171
NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659
G
Dnajc9
DnaJ heat shock protein family (Hsp40) member C9
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of DNAJC9 mRNA]
CTD
PMID:21858171
NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118
G
Dnmt1
DNA methyltransferase 1
increases expression
ISO
Piroxicam results in increased expression of DNMT1 mRNA
CTD
PMID:21858171
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
G
Donson
DNA replication fork stabilization factor DONSON
multiple interactions increases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in increased expression of DONSON mRNA]
CTD
PMID:21858171
NCBI chr11:30,919,834...30,933,150
Ensembl chr11:30,923,239...30,932,889
G
Dpm1
dolichyl-phosphate mannosyltransferase subunit 1, catalytic
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of DPM1 mRNA
CTD
PMID:21858171
NCBI chr 3:156,919,979...156,939,522
Ensembl chr 3:156,919,979...156,939,536
G
Dpp3
dipeptidylpeptidase 3
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of DPP3 mRNA]
CTD
PMID:21858171
NCBI chr 1:202,204,683...202,228,501
Ensembl chr 1:202,204,693...202,228,541
G
Dpyd
dihydropyrimidine dehydrogenase
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of DPYD mRNA
CTD
PMID:21858171
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
G
Dpysl2
dihydropyrimidinase-like 2
decreases expression
ISO
Piroxicam results in decreased expression of DPYSL2 mRNA
CTD
PMID:21858171
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
G
Dtl
denticleless E3 ubiquitin protein ligase homolog
decreases expression
ISO
Piroxicam results in decreased expression of DTL mRNA
CTD
PMID:21858171
NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890
G
Dtymk
deoxythymidylate kinase
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of DTYMK mRNA]
CTD
PMID:21858171
NCBI chr 9:94,315,552...94,324,386
Ensembl chr 9:94,315,552...94,324,870
G
Dusp1
dual specificity phosphatase 1
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of DUSP1 mRNA Cisplatin promotes the reaction [Piroxicam results in decreased expression of DUSP1 mRNA]
CTD
PMID:21858171
NCBI chr10:16,680,478...16,683,275
G
Dut
deoxyuridine triphosphatase
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of DUT mRNA]
CTD
PMID:21858171
NCBI chr 3:112,498,864...112,509,994
Ensembl chr 3:112,498,982...112,510,771
G
Dync1h1
dynein cytoplasmic 1 heavy chain 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of DYNC1H1 mRNA
CTD
PMID:21858171
NCBI chr 6:129,615,208...129,680,888
Ensembl chr 6:129,609,397...129,680,883
G
Ebna1bp2
EBNA1 binding protein 2
decreases expression
ISO
Piroxicam results in decreased expression of EBNA1BP2 mRNA
CTD
PMID:21858171
NCBI chr 5:132,148,164...132,152,730
Ensembl chr 5:132,148,143...132,153,267
G
Ebp
EBP, cholestenol delta-isomerase
decreases expression
ISO
Piroxicam results in decreased expression of EBP mRNA
CTD
PMID:21858171
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
G
Ect2
epithelial cell transforming 2
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of ECT2 mRNA Cisplatin promotes the reaction [Piroxicam results in decreased expression of ECT2 mRNA]
CTD
PMID:21858171
NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911
G
Eef1e1
eukaryotic translation elongation factor 1 epsilon 1
decreases expression
ISO
Piroxicam results in decreased expression of EEF1E1 mRNA
CTD
PMID:21858171
NCBI chr17:26,148,652...26,159,358
Ensembl chr17:26,148,633...26,215,720
G
Egfr
epidermal growth factor receptor
decreases expression multiple interactions
ISO EXP
Piroxicam results in decreased expression of EGFR mRNA Piroxicam promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein]
CTD
PMID:15309881 PMID:21858171
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
G
Eid1
EP300 interacting inhibitor of differentiation 1
decreases expression
ISO
Piroxicam results in decreased expression of EID1 mRNA
CTD
PMID:21858171
NCBI chr 3:112,922,961...112,924,680
Ensembl chr 3:112,922,668...112,924,752
G
Eif1ax
eukaryotic translation initiation factor 1A, X-linked
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of EIF1AX mRNA]
CTD
PMID:21858171
NCBI chr X:35,498,698...35,513,402
Ensembl chr X:35,498,517...35,513,335
G
Eif2s1
eukaryotic translation initiation factor 2 subunit alpha
decreases expression
ISO
Piroxicam results in decreased expression of EIF2S1 mRNA
CTD
PMID:21858171
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
G
Eif3j
eukaryotic translation initiation factor 3, subunit J
decreases expression
ISO
Piroxicam results in decreased expression of EIF3J mRNA
CTD
PMID:21858171
NCBI chr 3:108,985,103...109,007,341
Ensembl chr 3:108,985,118...109,007,953
G
Eif4a2
eukaryotic translation initiation factor 4A2
decreases expression
ISO
Piroxicam results in decreased expression of EIF4A2 mRNA
CTD
PMID:21858171
NCBI chr11:77,764,126...77,770,810
Ensembl chr11:77,764,124...77,770,781
G
Eif4b
eukaryotic translation initiation factor 4B
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of EIF4B mRNA
CTD
PMID:21858171
NCBI chr 7:133,206,637...133,228,436
G
Eif4e
eukaryotic translation initiation factor 4E
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of EIF4E mRNA]
CTD
PMID:21858171
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
G
Eif4e2
eukaryotic translation initiation factor 4E family member 2
decreases expression
ISO
Piroxicam results in decreased expression of EIF4E2 mRNA
CTD
PMID:21858171
NCBI chr 9:87,886,126...87,914,470
Ensembl chr 9:87,878,085...87,914,482
G
Eif5
eukaryotic translation initiation factor 5
decreases expression
ISO
Piroxicam results in decreased expression of EIF5 mRNA
CTD
PMID:21858171
NCBI chr 6:130,589,162...130,597,656
Ensembl chr 6:130,589,143...130,597,656
G
Eif5b
eukaryotic translation initiation factor 5B
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of EIF5B mRNA]
CTD
PMID:21858171
NCBI chr 9:40,222,769...40,277,482
Ensembl chr 9:40,222,898...40,277,482
G
Epas1
endothelial PAS domain protein 1
decreases expression
ISO
Piroxicam results in decreased expression of EPAS1 mRNA
CTD
PMID:21858171
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
G
Epb41l2
erythrocyte membrane protein band 4.1-like 2
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of EPB41L2 mRNA Cisplatin inhibits the reaction [Piroxicam results in decreased expression of EPB41L2 mRNA]
CTD
PMID:21858171
NCBI chr 1:19,863,010...20,037,795
Ensembl chr 1:19,863,009...20,037,721
G
Esm1
endothelial cell-specific molecule 1
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of ESM1 mRNA]
CTD
PMID:21858171
NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804
G
Ewsr1
EWS RNA-binding protein 1
decreases expression
ISO
Piroxicam results in decreased expression of EWSR1 mRNA
CTD
PMID:21858171
NCBI chr14:79,965,365...79,994,108
Ensembl chr14:79,965,368...79,994,544
G
Exoc3
exocyst complex component 3
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of EXOC3 mRNA
CTD
PMID:21858171
NCBI chr 1:29,091,298...29,122,056
Ensembl chr 1:29,091,294...29,122,045
G
Exosc8
exosome component 8
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of EXOSC8 mRNA
CTD
PMID:21858171
NCBI chr 2:138,930,405...138,937,009
Ensembl chr 2:138,930,405...138,936,928
G
Exosc9
exosome component 9
decreases expression
ISO
Piroxicam results in decreased expression of EXOSC9 mRNA
CTD
PMID:21858171
NCBI chr 2:119,416,028...119,426,981
Ensembl chr 2:119,388,715...119,427,051
G
Ezh2
enhancer of zeste 2 polycomb repressive complex 2 subunit
decreases expression
ISO
Piroxicam results in decreased expression of EZH2 mRNA
CTD
PMID:21858171
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
G
F8a1
coagulation factor VIII-associated 1
decreases expression
ISO
Piroxicam results in decreased expression of F8A1 mRNA
CTD
PMID:21858171
NCBI chr X:150,957,357...150,958,871
Ensembl chr X:150,916,679...150,960,168
G
Fam111a
FAM111 trypsin like peptidase A
increases expression
ISO
Piroxicam results in increased expression of FAM111A mRNA
CTD
PMID:21858171
NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547
G
Fanci
FA complementation group I
increases expression
ISO
Piroxicam results in increased expression of FANCI mRNA
CTD
PMID:21858171
NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640
G
Fancl
FA complementation group L
increases expression
ISO
Piroxicam results in increased expression of FANCL mRNA
CTD
PMID:21858171
NCBI chr14:100,249,733...100,317,958
Ensembl chr14:100,248,875...100,314,255
G
Fbxo9
f-box protein 9
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of FBXO9 mRNA]
CTD
PMID:21858171
NCBI chr 8:78,958,482...78,984,015
Ensembl chr 8:78,958,483...78,983,949
G
Fdft1
farnesyl diphosphate farnesyl transferase 1
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of FDFT1 mRNA]
CTD
PMID:21858171
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
G
Fdps
farnesyl diphosphate synthase
decreases expression
ISO
Piroxicam results in decreased expression of FDPS mRNA
CTD
PMID:21858171
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
G
Fdxr
ferredoxin reductase
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of FDXR mRNA
CTD
PMID:21858171
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
G
Fen1
flap structure-specific endonuclease 1
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of FEN1 mRNA]
CTD
PMID:21858171
NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
G
Fgf2
fibroblast growth factor 2
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of FGF2 mRNA]
CTD
PMID:21858171
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
G
Flii
FLII, actin remodeling protein
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of FLII mRNA
CTD
PMID:21858171
NCBI chr10:45,394,032...45,408,051
Ensembl chr10:45,394,032...45,407,970
G
Flnb
filamin B
decreases expression
ISO
Piroxicam results in decreased expression of FLNB mRNA
CTD
PMID:21858171
NCBI chr15:16,961,999...17,095,059
Ensembl chr15:16,962,003...17,095,006
G
Foxm1
forkhead box M1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of FOXM1 mRNA
CTD
PMID:21858171
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
G
Fst
follistatin
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of FST mRNA Cisplatin affects the reaction [Piroxicam results in decreased expression of FST mRNA]
CTD
PMID:21858171
NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571
G
Fut8
fucosyltransferase 8
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of FUT8 mRNA
CTD
PMID:21858171
NCBI chr 6:95,949,246...96,176,677
Ensembl chr 6:95,949,991...96,176,677
G
Fyn
FYN proto-oncogene, Src family tyrosine kinase
decreases expression
ISO
Piroxicam results in decreased expression of FYN mRNA
CTD
PMID:21858171
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
G
Gar1
GAR1 ribonucleoprotein
decreases expression
ISO
Piroxicam results in decreased expression of GAR1 mRNA
CTD
PMID:21858171
NCBI chr 2:218,375,231...218,382,509
Ensembl chr 2:218,375,353...218,382,524
G
Gbp1
guanylate binding protein 1
decreases expression
ISO
Piroxicam results in decreased expression of GBP1 mRNA
CTD
PMID:19192274
NCBI chr 2:231,398,136...231,432,773
Ensembl chr 2:231,398,163...231,432,131 Ensembl chr 2:231,398,163...231,432,131
G
Gcsh
glycine cleavage system protein H
decreases expression
ISO
Piroxicam results in decreased expression of GCSH mRNA
CTD
PMID:21858171
NCBI chr19:45,036,013...45,046,770
Ensembl chr19:45,036,011...45,046,792
G
Gdf15
growth differentiation factor 15
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of GDF15 mRNA]
CTD
PMID:21858171
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
G
Gins1
GINS complex subunit 1
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of GINS1 mRNA]
CTD
PMID:21858171
NCBI chr 3:139,724,513...139,745,930
Ensembl chr 3:139,724,490...139,745,936
G
Gins2
GINS complex subunit 2
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of GINS2 mRNA Cisplatin affects the reaction [Piroxicam results in decreased expression of GINS2 mRNA]
CTD
PMID:21858171
NCBI chr19:48,626,770...48,639,523
Ensembl chr19:48,626,770...48,639,339
G
Gins3
GINS complex subunit 3
increases expression
ISO
Piroxicam results in increased expression of GINS3 mRNA
CTD
PMID:21858171
NCBI chr19:9,420,085...9,428,621
Ensembl chr19:9,420,086...9,428,687
G
Gla
galactosidase, alpha
decreases expression
ISO
Piroxicam results in decreased expression of GLA mRNA
CTD
PMID:21858171
NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664
G
Glipr1
GLI pathogenesis-related 1
decreases expression
ISO
Piroxicam results in decreased expression of GLIPR1 mRNA
CTD
PMID:21858171
NCBI chr 7:47,487,342...47,498,974
Ensembl chr 7:47,487,345...47,498,429
G
Gm2a
ganglioside GM2 activator
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of GM2A mRNA
CTD
PMID:21858171
NCBI chr10:39,219,221...39,231,756
Ensembl chr10:39,219,243...39,231,757
G
Gmnn
geminin, DNA replication inhibitor
decreases expression
ISO
Piroxicam results in decreased expression of GMNN mRNA
CTD
PMID:21858171
NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054
G
Gng11
G protein subunit gamma 11
decreases expression
ISO
Piroxicam results in decreased expression of GNG11 mRNA
CTD
PMID:21858171
NCBI chr 4:32,023,003...32,028,443
Ensembl chr 4:32,023,003...32,028,442
G
Gpaa1
glycosylphosphatidylinositol anchor attachment 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of GPAA1 mRNA
CTD
PMID:21858171
NCBI chr 7:108,051,896...108,055,479
Ensembl chr 7:108,051,861...108,055,484
G
Gpc1
glypican 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of GPC1 mRNA
CTD
PMID:21858171
NCBI chr 9:93,396,234...93,424,047
Ensembl chr 9:93,396,234...93,424,047
G
Grn
granulin precursor
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of GRN mRNA]
CTD
PMID:21858171
NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775
G
Gsdme
gasdermin E
decreases expression
ISO
Piroxicam results in decreased expression of GSDME mRNA
CTD
PMID:19192274
NCBI chr 4:79,258,799...79,321,129
Ensembl chr 4:79,257,804...79,320,806
G
Gstt1
glutathione S-transferase theta 1
increases expression
EXP
Piroxicam results in increased expression of GSTT1 protein
CTD
PMID:9729437
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
G
Gtf2ird1
GTF2I repeat domain containing 1
decreases expression
ISO
Piroxicam results in decreased expression of GTF2IRD1 mRNA
CTD
PMID:21858171
NCBI chr12:22,254,113...22,361,052
Ensembl chr12:22,254,221...22,361,040
G
Gulp1
GULP PTB domain containing engulfment adaptor 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of GULP1 mRNA
CTD
PMID:21858171
NCBI chr 9:46,622,699...46,899,005
Ensembl chr 9:46,622,669...46,899,005
G
H2ax
H2A.X variant histone
decreases expression
ISO
Piroxicam results in decreased expression of H2AX mRNA
CTD
PMID:21858171
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
G
Hat1
histone acetyltransferase 1
decreases expression
ISO
Piroxicam results in decreased expression of HAT1 mRNA
CTD
PMID:21858171
NCBI chr 3:56,217,344...56,265,021
Ensembl chr 3:56,217,342...56,275,517
G
Hexim1
HEXIM P-TEFb complex subunit 1
decreases expression
ISO
Piroxicam results in decreased expression of HEXIM1 mRNA
CTD
PMID:21858171
NCBI chr10:88,062,808...88,064,920
Ensembl chr10:88,062,803...88,066,189
G
Hilpda
hypoxia inducible lipid droplet-associated
decreases expression
ISO
Piroxicam results in decreased expression of HILPDA mRNA
CTD
PMID:19192274
NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557
G
Hmga2
high mobility group AT-hook 2
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of HMGA2 mRNA
CTD
PMID:21858171
NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784
G
Hmgcr
3-hydroxy-3-methylglutaryl-CoA reductase
decreases expression
ISO
Piroxicam results in decreased expression of HMGCR mRNA
CTD
PMID:21858171
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
G
Hmgn3
high mobility group nucleosomal binding domain 3
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of HMGN3 mRNA]
CTD
PMID:21858171
NCBI chr 8:84,022,493...84,059,329
Ensembl chr 8:84,022,495...84,062,976
G
Hmmr
hyaluronan-mediated motility receptor
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of HMMR mRNA
CTD
PMID:21858171
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
G
Hnrnpa3
heterogeneous nuclear ribonucleoprotein A3
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of HNRNPA3 mRNA]
CTD
PMID:21858171
NCBI chr 3:60,578,574...60,588,755
Ensembl chr 3:60,578,673...60,588,306
G
Hnrnpd
heterogeneous nuclear ribonucleoprotein D
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of HNRNPD mRNA]
CTD
PMID:21858171
NCBI chr14:9,615,375...9,638,975
Ensembl chr14:9,615,479...9,633,786
G
Hnrnpl
heterogeneous nuclear ribonucleoprotein L
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of HNRNPL mRNA
CTD
PMID:21858171
NCBI chr 1:84,098,558...84,111,568
Ensembl chr 1:84,100,879...84,111,553
G
Hoxa9
homeobox A9
decreases expression
ISO
Piroxicam results in decreased expression of HOXA9 mRNA
CTD
PMID:21858171
NCBI chr 4:81,323,235...81,329,344
Ensembl chr 4:81,323,382...81,326,358
G
Hs2st1
heparan sulfate 2-O-sulfotransferase 1
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of HS2ST1 mRNA]
CTD
PMID:21858171
NCBI chr 2:233,508,018...233,641,769
Ensembl chr 2:233,508,021...233,641,769
G
Hsbp1
heat shock factor binding protein 1
decreases expression
ISO
Piroxicam results in decreased expression of HSBP1 mRNA
CTD
PMID:21858171
NCBI chr19:47,401,039...47,405,373
Ensembl chr19:47,400,966...47,435,821
G
Hsd11b1
hydroxysteroid 11-beta dehydrogenase 1
decreases expression
ISO
Piroxicam results in decreased expression of HSD11B1 mRNA
CTD
PMID:19192274
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
G
Hsd17b11
hydroxysteroid (17-beta) dehydrogenase 11
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of HSD17B11 mRNA
CTD
PMID:21858171
NCBI chr14:5,693,304...5,743,157
Ensembl chr14:5,711,964...5,743,161
G
Hspa14
heat shock protein family A (Hsp70) member 14
increases expression multiple interactions
ISO
Piroxicam results in increased expression of HSPA14 mRNA Cisplatin inhibits the reaction [Piroxicam results in increased expression of HSPA14 mRNA]
CTD
PMID:21858171
NCBI chr17:74,728,945...74,749,727
Ensembl chr17:74,728,899...74,749,727
G
Hspa1a
heat shock protein family A (Hsp70) member 1A
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of HSPA1A mRNA Cisplatin affects the reaction [Piroxicam results in decreased expression of HSPA1A mRNA]
CTD
PMID:21858171
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
G
Hspa1b
heat shock protein family A (Hsp70) member 1B
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of HSPA1B mRNA]
CTD
PMID:21858171
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
G
Hspa4l
heat shock protein family A (Hsp70) member 4 like
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of HSPA4L mRNA
CTD
PMID:21858171
NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084
G
Hspa9
heat shock protein family A (Hsp70) member 9
decreases expression
ISO
Piroxicam results in decreased expression of HSPA9 mRNA
CTD
PMID:21858171
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
G
Hspe1
heat shock protein family E (Hsp10) member 1
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of HSPE1 mRNA]
CTD
PMID:21858171
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
G
Hsph1
heat shock protein family H (Hsp110) member 1
decreases expression
ISO
Piroxicam results in decreased expression of HSPH1 mRNA
CTD
PMID:21858171
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
G
Idh3a
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha
decreases expression
ISO
Piroxicam results in decreased expression of IDH3A mRNA
CTD
PMID:21858171
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
G
Idi1
isopentenyl-diphosphate delta isomerase 1
decreases expression
ISO
Piroxicam results in decreased expression of IDI1 mRNA
CTD
PMID:21858171
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
G
Ifi27
interferon, alpha-inducible protein 27
decreases expression
ISO
Piroxicam results in decreased expression of IFI27 mRNA
CTD
PMID:19192274
NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294
G
Ifi44l
interferon-induced protein 44-like
decreases expression
ISO
Piroxicam results in decreased expression of IFI44L mRNA
CTD
PMID:19192274
NCBI chr 2:240,668,742...240,706,425
Ensembl chr 2:240,668,713...240,706,359
G
Il1rn
interleukin 1 receptor antagonist
decreases expression
ISO
Piroxicam results in decreased expression of IL1RN mRNA
CTD
PMID:19192274
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
G
Il23a
interleukin 23 subunit alpha
decreases expression
ISO
Piroxicam results in decreased expression of IL23A mRNA
CTD
PMID:19192274
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
G
Il6
interleukin 6
decreases expression
ISO
Piroxicam results in decreased expression of IL6 mRNA; Piroxicam results in decreased expression of IL6 protein
CTD
PMID:19192274
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Ilf3
interleukin enhancer binding factor 3
decreases expression
ISO
Piroxicam results in decreased expression of ILF3 mRNA
CTD
PMID:21858171
NCBI chr 8:19,922,409...19,960,495
Ensembl chr 8:19,922,460...19,960,350
G
Insig1
insulin induced gene 1
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of INSIG1 mRNA]
CTD
PMID:21858171
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
G
Ipo7
importin 7
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of IPO7 mRNA Cisplatin affects the reaction [Piroxicam results in decreased expression of IPO7 mRNA]
CTD
PMID:21858171
NCBI chr 1:164,062,702...164,102,938
Ensembl chr 1:164,062,702...164,102,938
G
Iqcb1
IQ motif containing B1
decreases expression
ISO
Piroxicam results in decreased expression of IQCB1 mRNA
CTD
PMID:21858171
NCBI chr11:63,905,595...63,960,141
Ensembl chr11:63,905,590...63,960,093
G
Irs2
insulin receptor substrate 2
decreases expression
ISO
Piroxicam results in decreased expression of IRS2 mRNA
CTD
PMID:21858171
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
G
Isg15
ISG15 ubiquitin-like modifier
decreases expression
ISO
Piroxicam results in decreased expression of ISG15 mRNA
CTD
PMID:19192274
NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
G
Isg20
interferon stimulated exonuclease gene 20
decreases expression
ISO
Piroxicam results in decreased expression of ISG20 mRNA
CTD
PMID:19192274
NCBI chr 1:132,829,303...132,837,027
Ensembl chr 1:132,815,123...132,837,027
G
Itgb3bp
integrin subunit beta 3 binding protein
decreases expression
ISO
Piroxicam results in decreased expression of ITGB3BP mRNA
CTD
PMID:21858171
NCBI chr 5:114,460,217...114,525,538
Ensembl chr 5:114,460,221...114,525,704
G
Jag2
jagged canonical Notch ligand 2
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of JAG2 mRNA
CTD
PMID:21858171
NCBI chr 6:131,983,059...132,005,665
Ensembl chr 6:131,983,056...132,005,818
G
Jmjd6
jumonji domain containing 6, arginine demethylase and lysine hydroxylase
increases expression
ISO
Piroxicam results in increased expression of JMJD6 mRNA
CTD
PMID:21858171
NCBI chr10:102,041,131...102,047,182
Ensembl chr10:102,041,120...102,047,182
G
Jund
JunD proto-oncogene, AP-1 transcription factor subunit
decreases expression
ISO
Piroxicam results in decreased expression of JUND mRNA
CTD
PMID:21858171
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
G
Kcnma1
potassium calcium-activated channel subfamily M alpha 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of KCNMA1 mRNA
CTD
PMID:21858171
NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198
G
Kdelr2
KDEL endoplasmic reticulum protein retention receptor 2
decreases expression
ISO
Piroxicam results in decreased expression of KDELR2 mRNA
CTD
PMID:21858171
NCBI chr12:11,138,820...11,157,117
Ensembl chr12:11,138,820...11,157,153
G
Kif11
kinesin family member 11
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of KIF11 mRNA Cisplatin affects the reaction [Piroxicam results in decreased expression of KIF11 mRNA]
CTD
PMID:21858171
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
G
Kif14
kinesin family member 14
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of KIF14 mRNA]
CTD
PMID:21858171
NCBI chr13:47,926,975...47,990,598
Ensembl chr13:47,927,044...47,989,164
G
Kif18a
kinesin family member 18A
decreases expression
ISO
Piroxicam results in decreased expression of KIF18A mRNA
CTD
PMID:21858171
NCBI chr 3:95,764,388...95,824,756
Ensembl chr 3:95,764,388...95,824,582
G
Kif20a
kinesin family member 20A
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of KIF20A mRNA]
CTD
PMID:21858171
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
G
Kif23
kinesin family member 23
decreases expression
ISO
Piroxicam results in decreased expression of KIF23 mRNA
CTD
PMID:21858171
NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
G
Kif2c
kinesin family member 2C
increases expression
ISO
Piroxicam results in increased expression of KIF2C mRNA
CTD
PMID:21858171
NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
G
Kif4a
kinesin family member 4A
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of KIF4A mRNA
CTD
PMID:21858171
NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139
G
Klf4
KLF transcription factor 4
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of KLF4 mRNA
CTD
PMID:21858171
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
G
Klhl21
kelch-like family member 21
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of KLHL21 mRNA
CTD
PMID:21858171
NCBI chr 5:162,514,888...162,523,545
Ensembl chr 5:162,514,765...162,523,545
G
Kpna1
karyopherin subunit alpha 1
decreases expression
ISO
Piroxicam results in decreased expression of KPNA1 mRNA
CTD
PMID:21858171
NCBI chr11:64,715,844...64,774,647
Ensembl chr11:64,717,563...64,774,623
G
Kpna2
karyopherin subunit alpha 2
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of KPNA2 mRNA Cisplatin affects the reaction [Piroxicam results in decreased expression of KPNA2 mRNA]
CTD
PMID:21858171
NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150
G
Kpnb1
karyopherin subunit beta 1
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of KPNB1 mRNA]
CTD
PMID:21858171
NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605
G
Krr1
KRR1, small subunit processome component homolog
increases expression
ISO
Piroxicam results in increased expression of KRR1 mRNA
CTD
PMID:21858171
NCBI chr 7:47,475,557...47,486,996
Ensembl chr 7:47,475,557...47,486,985
G
Lamb3
laminin subunit beta 3
decreases expression
ISO
Piroxicam results in decreased expression of LAMB3 mRNA
CTD
PMID:19192274
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
G
Lamc1
laminin subunit gamma 1
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of LAMC1 mRNA Cisplatin inhibits the reaction [Piroxicam results in decreased expression of LAMC1 mRNA]
CTD
PMID:21858171
NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492
G
Lbr
lamin B receptor
multiple interactions increases expression
ISO
Cisplatin affects the reaction [Piroxicam results in increased expression of LBR mRNA]
CTD
PMID:21858171
NCBI chr13:93,539,386...93,564,026
Ensembl chr13:93,538,920...93,564,017
G
Ldlr
low density lipoprotein receptor
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of LDLR mRNA]
CTD
PMID:21858171
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
G
Lgals3bp
galectin 3 binding protein
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of LGALS3BP mRNA
CTD
PMID:21858171
NCBI chr10:103,619,912...103,629,251
Ensembl chr10:103,619,908...103,629,256
G
Lhfpl2
LHFPL tetraspan subfamily member 2
increases expression
ISO
Piroxicam results in increased expression of LHFPL2 mRNA
CTD
PMID:21858171
NCBI chr 2:25,281,771...25,428,128
Ensembl chr 2:25,281,901...25,427,950
G
Lrba
LPS responsive beige-like anchor protein
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of LRBA mRNA
CTD
PMID:21858171
NCBI chr 2:171,623,668...172,202,576
Ensembl chr 2:171,621,507...172,202,724
G
Lxn
latexin
increases expression
ISO
Piroxicam results in increased expression of LXN mRNA
CTD
PMID:19192274
NCBI chr 2:151,727,556...151,733,426
Ensembl chr 2:151,727,102...151,733,460
G
Ly6e
lymphocyte antigen 6 family member E
decreases expression
ISO
Piroxicam results in decreased expression of LY6E mRNA
CTD
PMID:19192274
NCBI chr 7:106,935,530...106,939,689
Ensembl chr 7:106,935,761...106,939,689
G
Mad2l1
mitotic arrest deficient 2 like 1
increases expression
ISO
Piroxicam results in increased expression of MAD2L1 mRNA
CTD
PMID:21858171
NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470
G
Magoh
mago homolog, exon junction complex subunit
increases expression
ISO
Piroxicam results in increased expression of MAGOH mRNA
CTD
PMID:21858171
NCBI chr 5:122,639,268...122,646,650
Ensembl chr 5:122,639,308...122,646,617
G
Manf
mesencephalic astrocyte-derived neurotrophic factor
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of MANF mRNA]
CTD
PMID:21858171
NCBI chr 8:107,500,856...107,551,595
Ensembl chr 8:107,548,352...107,551,438
G
Marcks
myristoylated alanine rich protein kinase C substrate
decreases expression
ISO
Piroxicam results in decreased expression of MARCKS mRNA
CTD
PMID:19192274
NCBI chr20:40,685,315...40,691,012
Ensembl chr20:40,685,315...40,691,012
G
Mars1
methionyl-tRNA synthetase 1
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of MARS1 mRNA]
CTD
PMID:21858171
NCBI chr 7:63,121,142...63,138,550
Ensembl chr 7:63,121,142...63,138,495
G
Mcam
melanoma cell adhesion molecule
decreases expression
ISO
Piroxicam results in decreased expression of MCAM mRNA
CTD
PMID:21858171
NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571
G
Mcm3
minichromosome maintenance complex component 3
decreases expression
ISO
Piroxicam results in decreased expression of MCM3 mRNA
CTD
PMID:21858171
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
G
Mcm4
minichromosome maintenance complex component 4
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of MCM4 mRNA Cisplatin inhibits the reaction [Piroxicam results in decreased expression of MCM4 mRNA]
CTD
PMID:21858171
NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144
G
Mcm5
minichromosome maintenance complex component 5
increases expression
ISO
Piroxicam results in increased expression of MCM5 mRNA
CTD
PMID:21858171
NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389
G
Mcm6
minichromosome maintenance complex component 6
decreases expression
ISO
Piroxicam results in decreased expression of MCM6 mRNA
CTD
PMID:21858171
NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960
G
Mdk
midkine
increases expression
ISO
Piroxicam results in increased expression of MDK mRNA
CTD
PMID:21858171
NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130
G
Med21
mediator complex subunit 21
decreases expression
ISO
Piroxicam results in decreased expression of MED21 mRNA
CTD
PMID:21858171
NCBI chr 4:179,560,509...179,583,811
Ensembl chr 4:179,560,579...179,567,548
G
Med27
mediator complex subunit 27
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of MED27 mRNA
CTD
PMID:21858171
NCBI chr 3:12,629,593...12,803,340
Ensembl chr 3:12,629,603...12,803,339
G
Meis2
Meis homeobox 2
decreases expression
ISO
Piroxicam results in decreased expression of MEIS2 mRNA
CTD
PMID:21858171
NCBI chr 3:102,742,904...102,944,833
Ensembl chr 3:102,742,900...102,949,696
G
Mest
mesoderm specific transcript
decreases expression
ISO
Piroxicam results in decreased expression of MEST mRNA
CTD
PMID:21858171
NCBI chr 4:59,354,445...59,364,919
Ensembl chr 4:59,354,447...59,366,145
G
Met
MET proto-oncogene, receptor tyrosine kinase
decreases expression
ISO
Piroxicam results in decreased expression of MET mRNA
CTD
PMID:19192274
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
G
Mgat2
alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of MGAT2 mRNA Cisplatin inhibits the reaction [Piroxicam results in decreased expression of MGAT2 mRNA]
CTD
PMID:21858171
NCBI chr 6:87,656,360...87,658,849
Ensembl chr 6:87,656,349...87,658,177
G
Mink1
misshapen-like kinase 1
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of MINK1 mRNA]
CTD
PMID:21858171
NCBI chr10:55,278,293...55,330,782
Ensembl chr10:55,278,391...55,330,782
G
Mis18a
MIS18 kinetochore protein A
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of MIS18A mRNA]
CTD
PMID:21858171
NCBI chr11:29,968,030...29,981,058
Ensembl chr11:29,967,701...29,981,062
G
Mki67
marker of proliferation Ki-67
decreases expression
ISO
Piroxicam results in decreased expression of MKI67 mRNA
CTD
PMID:21858171
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
G
Mllt11
MLLT11, transcription factor 7 cofactor
decreases expression
ISO
Piroxicam results in decreased expression of MLLT11 mRNA
CTD
PMID:21858171
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
G
Mmp10
matrix metallopeptidase 10
decreases expression
ISO
Piroxicam results in decreased expression of MMP10 mRNA
CTD
PMID:19192274
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
G
Mmp2
matrix metallopeptidase 2
decreases activity
ISO
Piroxicam results in decreased activity of MMP2 protein
CTD
PMID:15990687
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
G
Mob1a
MOB kinase activator 1A
decreases expression
ISO
Piroxicam results in decreased expression of MOB1A mRNA
CTD
PMID:21858171
NCBI chr 4:115,831,581...115,848,561
Ensembl chr 4:115,831,551...115,848,561 Ensembl chr 1:115,831,551...115,848,561
G
Mpo
myeloperoxidase
decreases activity increases expression multiple interactions increases activity
EXP
Piroxicam results in decreased activity of MPO Piroxicam results in increased expression of MPO protein pantoprazole inhibits the reaction [Piroxicam results in increased expression of MPO protein] Piroxicam results in increased activity of MPO protein
CTD
PMID:11996850 PMID:15309881 PMID:16080005
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
G
Mr1
major histocompatibility complex, class I-related
affects expression
ISO
Piroxicam affects the expression of MR1 mRNA
CTD
PMID:25811541
NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970
G
Mrpl13
mitochondrial ribosomal protein L13
decreases expression
ISO
Piroxicam results in decreased expression of MRPL13 mRNA
CTD
PMID:21858171
NCBI chr 7:86,951,541...86,973,147
Ensembl chr 7:86,951,541...86,973,577
G
Mrpl16
mitochondrial ribosomal protein L16
decreases expression
ISO
Piroxicam results in decreased expression of MRPL16 mRNA
CTD
PMID:21858171
NCBI chr 1:208,633,671...208,638,483
Ensembl chr 1:208,633,586...208,640,667
G
Msh2
mutS homolog 2
decreases expression
ISO
Piroxicam results in decreased expression of MSH2 mRNA
CTD
PMID:21858171
NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
G
Msh6
mutS homolog 6
decreases expression
ISO
Piroxicam results in decreased expression of MSH6 mRNA
CTD
PMID:21858171
NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956
G
Msmo1
methylsterol monooxygenase 1
decreases expression
ISO
Piroxicam results in decreased expression of MSMO1 mRNA
CTD
PMID:21858171
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
G
Mt2A
metallothionein 2A
decreases expression
ISO
Piroxicam results in decreased expression of MT2A mRNA
CTD
PMID:21858171
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
G
Mx1
MX dynamin like GTPase 1
decreases expression
ISO
Piroxicam results in decreased expression of MX1 mRNA
CTD
PMID:19192274
NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507
G
Myc
MYC proto-oncogene, bHLH transcription factor
multiple interactions
EXP
Piroxicam inhibits the reaction [Azoxymethane results in increased expression of MYC mRNA]; Piroxicam inhibits the reaction [Azoxymethane results in increased expression of MYC protein]
CTD
PMID:12189186
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
G
Mycbp
Myc binding protein
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of MYCBP mRNA]
CTD
PMID:21858171
NCBI chr 5:136,135,955...136,143,163
Ensembl chr 5:136,135,931...136,145,616
G
Naa15
N(alpha)-acetyltransferase 15, NatA auxiliary subunit
increases expression
ISO
Piroxicam results in increased expression of NAA15 mRNA
CTD
PMID:21858171
NCBI chr 2:135,458,018...135,520,756
Ensembl chr 2:135,457,948...135,520,756
G
Nab1
Ngfi-A binding protein 1
decreases expression
ISO
Piroxicam results in decreased expression of NAB1 mRNA
CTD
PMID:21858171
NCBI chr 9:49,053,579...49,093,078
Ensembl chr 9:49,053,758...49,092,098
G
Nap1l1
nucleosome assembly protein 1-like 1
increases expression
ISO
Piroxicam results in increased expression of NAP1L1 mRNA
CTD
PMID:21858171
NCBI chr 7:46,933,278...46,957,853
Ensembl chr 7:46,933,356...46,956,593
G
Nasp
nuclear autoantigenic sperm protein
decreases expression
ISO
Piroxicam results in decreased expression of NASP mRNA
CTD
PMID:21858171
NCBI chr 5:130,057,363...130,083,003
Ensembl chr 5:130,057,363...130,082,928
G
Nbr1
NBR1, autophagy cargo receptor
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of NBR1 mRNA]
CTD
PMID:21858171
NCBI chr10:86,477,775...86,506,418
Ensembl chr10:86,478,290...86,506,412
G
Ncapd3
non-SMC condensin II complex, subunit D3
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of NCAPD3 mRNA]
CTD
PMID:21858171
NCBI chr 8:25,437,067...25,506,375
Ensembl chr 8:25,437,123...25,506,373
G
Ncapg
non-SMC condensin I complex, subunit G
decreases expression
ISO
Piroxicam results in decreased expression of NCAPG mRNA
CTD
PMID:21858171
NCBI chr14:65,403,930...65,432,902
Ensembl chr14:65,404,163...65,432,902
G
Ncaph
non-SMC condensin I complex, subunit H
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of NCAPH mRNA]
CTD
PMID:21858171
NCBI chr 3:114,371,937...114,399,178
Ensembl chr 3:114,371,941...114,399,180
G
Nck1
NCK adaptor protein 1
decreases expression
ISO
Piroxicam results in decreased expression of NCK1 mRNA
CTD
PMID:21858171
NCBI chr 8:101,018,610...101,079,237
Ensembl chr 8:101,018,702...101,079,300
G
Ndc80
NDC80 kinetochore complex component
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of NDC80 mRNA]
CTD
PMID:21858171
NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924
G
Ndufa4l2
NDUFA4, mitochondrial complex associated like 2
decreases expression
ISO
Piroxicam results in decreased expression of NDUFA4L2 mRNA
CTD
PMID:19192274
NCBI chr 7:63,351,021...63,359,010
Ensembl chr 7:63,356,883...63,359,010
G
Ndufa5
NADH:ubiquinone oxidoreductase subunit A5
decreases expression
ISO
Piroxicam results in decreased expression of NDUFA5 mRNA
CTD
PMID:21858171
NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598 Ensembl chr 5:52,995,546...53,005,598
G
Nek9
NIMA-related kinase 9
increases expression
ISO
Piroxicam results in increased expression of NEK9 mRNA
CTD
PMID:21858171
NCBI chr 6:104,944,056...104,984,538
Ensembl chr 6:104,944,056...104,984,538
G
Net1
neuroepithelial cell transforming 1
decreases expression
ISO
Piroxicam results in decreased expression of NET1 mRNA
CTD
PMID:21858171
NCBI chr17:66,341,251...66,370,445
Ensembl chr17:66,340,728...66,370,441
G
Nfatc3
nuclear factor of activated T-cells 3
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of NFATC3 mRNA
CTD
PMID:21858171
NCBI chr19:33,960,643...34,035,150
Ensembl chr19:33,960,852...34,035,150
G
Nfe2l1
NFE2 like bZIP transcription factor 1
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of NFE2L1 mRNA]
CTD
PMID:21858171
NCBI chr10:81,796,055...81,812,926
Ensembl chr10:81,800,366...81,832,318
G
Niban1
niban apoptosis regulator 1
decreases expression
ISO
Piroxicam results in decreased expression of NIBAN1 mRNA
CTD
PMID:21858171
NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729
G
Nid2
nidogen 2
increases expression
ISO
Piroxicam results in increased expression of NID2 mRNA
CTD
PMID:19192274
NCBI chr15:4,458,082...4,513,808
Ensembl chr15:4,458,084...4,513,843
G
Nisch
nischarin
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of NISCH mRNA
CTD
PMID:21858171
NCBI chr16:6,364,370...6,400,675
Ensembl chr16:6,364,374...6,400,668
G
Nkx3-1
NK3 homeobox 1
multiple interactions
ISO
Piroxicam inhibits the reaction [mibolerone results in increased expression of NKX3-1 mRNA]
CTD
PMID:10537180
NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441
G
Nle1
notchless homolog 1
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of NLE1 mRNA]
CTD
PMID:21858171
NCBI chr10:67,834,059...67,844,771
Ensembl chr10:67,834,062...67,842,658
G
Nme7
NME/NM23 family member 7
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of NME7 mRNA
CTD
PMID:21858171
NCBI chr13:76,657,303...76,786,768
Ensembl chr13:76,657,367...76,786,765
G
Nmt2
N-myristoyltransferase 2
decreases expression
ISO
Piroxicam results in decreased expression of NMT2 mRNA
CTD
PMID:21858171
NCBI chr17:74,917,833...74,964,788
Ensembl chr17:74,917,833...74,961,080
G
Nol8
nucleolar protein 8
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of NOL8 mRNA
CTD
PMID:21858171
NCBI chr17:14,990,394...15,013,784
Ensembl chr17:14,990,417...15,013,848
G
Nolc1
nucleolar and coiled-body phosphoprotein 1
increases expression
ISO
Piroxicam results in increased expression of NOLC1 mRNA
CTD
PMID:21858171
NCBI chr 1:244,921,275...244,932,089
Ensembl chr 1:244,921,377...244,932,088
G
Npdc1
neural proliferation, differentiation and control, 1
decreases expression
ISO
Piroxicam results in decreased expression of NPDC1 mRNA
CTD
PMID:21858171
NCBI chr 3:8,220,446...8,226,446
Ensembl chr 3:8,213,663...8,226,866
G
Nr4a3
nuclear receptor subfamily 4, group A, member 3
decreases expression
ISO
Piroxicam results in decreased expression of NR4A3 mRNA
CTD
PMID:19192274
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
G
Nrip1
nuclear receptor interacting protein 1
decreases expression
ISO
Piroxicam results in decreased expression of NRIP1 mRNA
CTD
PMID:21858171
NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761
G
Nrp1
neuropilin 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of NRP1 mRNA
CTD
PMID:21858171
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
G
Nsl1
NSL1 component of MIS12 kinetochore complex
decreases expression
ISO
Piroxicam results in decreased expression of NSL1 mRNA
CTD
PMID:21858171
NCBI chr13:102,649,050...102,674,059
Ensembl chr13:102,649,058...102,674,054
G
Nudt21
nudix hydrolase 21
decreases expression
ISO
Piroxicam results in decreased expression of NUDT21 mRNA
CTD
PMID:21858171
NCBI chr19:10,974,800...10,993,841
Ensembl chr19:10,974,241...10,991,682
G
Nup160
nucleoporin 160
decreases expression
ISO
Piroxicam results in decreased expression of NUP160 mRNA
CTD
PMID:21858171
NCBI chr 3:76,665,786...76,729,296
Ensembl chr 3:76,665,786...76,724,565
G
Nup50
nucleoporin 50
decreases expression
ISO
Piroxicam results in decreased expression of NUP50 mRNA
CTD
PMID:21858171
NCBI chr 7:116,047,960...116,065,231
Ensembl chr 7:116,048,021...116,066,905
G
Nup85
nucleoporin 85
decreases expression
ISO
Piroxicam results in decreased expression of NUP85 mRNA
CTD
PMID:21858171
NCBI chr10:100,806,482...100,825,029
Ensembl chr10:100,806,437...100,825,043
G
Nup88
nucleoporin 88
decreases expression
ISO
Piroxicam results in decreased expression of NUP88 mRNA
CTD
PMID:21858171
NCBI chr10:55,667,903...55,692,249
Ensembl chr10:55,667,906...55,692,257
G
Nxt2
nuclear transport factor 2-like export factor 2
increases expression
ISO
Piroxicam results in increased expression of NXT2 mRNA
CTD
PMID:21858171
NCBI chr X:105,855,616...105,862,902
Ensembl chr X:105,855,608...105,862,899
G
Ogt
O-linked N-acetylglucosamine (GlcNAc) transferase
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of OGT mRNA]
CTD
PMID:21858171
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
G
Olfml2b
olfactomedin-like 2B
increases expression
ISO
Piroxicam results in increased expression of OLFML2B mRNA
CTD
PMID:19192274
NCBI chr13:82,869,414...82,906,607
Ensembl chr13:82,869,433...82,906,607
G
Opa1
OPA1, mitochondrial dynamin like GTPase
decreases expression
ISO
Piroxicam results in decreased expression of OPA1 mRNA
CTD
PMID:21858171
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
G
Optn
optineurin
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of OPTN mRNA Cisplatin affects the reaction [Piroxicam results in decreased expression of OPTN mRNA]
CTD
PMID:21858171
NCBI chr17:73,209,572...73,260,251
Ensembl chr17:73,209,575...73,260,251
G
Orc6
origin recognition complex, subunit 6
decreases expression
ISO
Piroxicam results in decreased expression of ORC6 mRNA
CTD
PMID:21858171
NCBI chr19:21,757,867...21,765,638
Ensembl chr19:21,757,866...21,765,662
G
Pa2g4
proliferation-associated 2G4
increases expression
ISO
Piroxicam results in increased expression of PA2G4 mRNA
CTD
PMID:21858171
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
G
Pacsin2
protein kinase C and casein kinase substrate in neurons 2
increases expression
ISO
Piroxicam results in increased expression of PACSIN2 mRNA
CTD
PMID:21858171
NCBI chr 7:114,505,525...114,599,087
Ensembl chr 7:114,505,152...114,598,546
G
Pafah1b1
platelet-activating factor acetylhydrolase 1b, regulatory subunit 1
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of PAFAH1B1 mRNA Cisplatin affects the reaction [Piroxicam results in decreased expression of PAFAH1B1 mRNA]
CTD
PMID:21858171
NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808
G
Palld
palladin, cytoskeletal associated protein
decreases expression
ISO
Piroxicam results in decreased expression of PALLD mRNA
CTD
PMID:21858171
NCBI chr16:28,228,006...28,621,349
Ensembl chr16:27,981,354...28,621,337
G
Pank2
pantothenate kinase 2
increases expression
ISO
Piroxicam results in increased expression of PANK2 mRNA
CTD
PMID:21858171
NCBI chr 3:118,483,382...118,519,551
Ensembl chr 3:118,483,444...118,518,320
G
Paxip1
PAX interacting protein 1
decreases expression
ISO
Piroxicam results in decreased expression of PAXIP1 mRNA
CTD
PMID:21858171
NCBI chr 4:7,525,132...7,576,659
Ensembl chr 4:7,525,004...7,576,548
G
Pbk
PDZ binding kinase
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of PBK mRNA Cisplatin promotes the reaction [Piroxicam results in decreased expression of PBK mRNA]
CTD
PMID:21858171
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
G
Pbx1
PBX homeobox 1
increases expression
ISO
Piroxicam results in increased expression of PBX1 mRNA
CTD
PMID:21858171
NCBI chr13:80,278,766...80,588,563
Ensembl chr13:80,278,770...80,588,594
G
Pcgf2
polycomb group ring finger 2
increases expression
ISO
Piroxicam results in increased expression of PCGF2 mRNA
CTD
PMID:21858171
NCBI chr10:82,682,563...82,694,563
Ensembl chr10:82,683,553...82,693,406
G
Pclaf
PCNA clamp associated factor
decreases expression
ISO
Piroxicam results in decreased expression of PCLAF mRNA
CTD
PMID:21858171
NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994 Ensembl chr 8:66,420,587...66,432,994
G
Pcna
proliferating cell nuclear antigen
decreases expression
ISO
Piroxicam results in decreased expression of PCNA mRNA
CTD
PMID:21858171
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
G
Pdss1
decaprenyl diphosphate synthase subunit 1
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of PDSS1 mRNA]
CTD
PMID:21858171
NCBI chr17:85,059,953...85,098,739
Ensembl chr17:85,060,106...85,098,730
G
Pgls
6-phosphogluconolactonase
increases expression
ISO
Piroxicam results in increased expression of PGLS mRNA
CTD
PMID:21858171
NCBI chr16:18,300,317...18,305,803
Ensembl chr16:18,300,317...18,305,803
G
Pgrmc2
progesterone receptor membrane component 2
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of PGRMC2 mRNA]
CTD
PMID:21858171
NCBI chr 2:124,068,257...124,084,155
Ensembl chr 2:124,068,260...124,084,155
G
Phb1
prohibitin 1
decreases expression
ISO
Piroxicam results in decreased expression of PHB1 mRNA
CTD
PMID:21858171
NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042
G
Phgdh
phosphoglycerate dehydrogenase
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of PHGDH mRNA]
CTD
PMID:21858171
NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944
G
Phip
pleckstrin homology domain interacting protein
increases expression
ISO
Piroxicam results in increased expression of PHIP mRNA
CTD
PMID:21858171
NCBI chr 8:83,776,802...83,891,192
Ensembl chr 8:83,781,465...83,894,283
G
Phlda2
pleckstrin homology-like domain, family A, member 2
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of PHLDA2 mRNA Cisplatin affects the reaction [Piroxicam results in decreased expression of PHLDA2 mRNA]
CTD
PMID:21858171
NCBI chr 1:198,696,897...198,699,292
Ensembl chr 1:198,696,897...198,697,836
G
Pigp
phosphatidylinositol glycan anchor biosynthesis, class P
decreases expression
ISO
Piroxicam results in decreased expression of PIGP mRNA
CTD
PMID:21858171
NCBI chr11:33,682,943...33,689,111
Ensembl chr11:33,682,948...33,689,321
G
Pik3r4
phosphoinositide-3-kinase, regulatory subunit 4
decreases expression
ISO
Piroxicam results in decreased expression of PIK3R4 mRNA
CTD
PMID:21858171
NCBI chr 8:106,267,908...106,316,585
Ensembl chr 8:106,267,954...106,316,584
G
Pilra
paired immunoglobin-like type 2 receptor alpha
decreases expression
ISO
Piroxicam results in decreased expression of PILRA mRNA
CTD
PMID:19192274
NCBI chr12:17,787,169...17,798,149
Ensembl chr12:17,787,127...17,798,094
G
Pink1
PTEN induced kinase 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of PINK1 mRNA
CTD
PMID:21858171
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
G
Plat
plasminogen activator, tissue type
decreases expression
ISO
Piroxicam results in decreased expression of PLAT mRNA
CTD
PMID:21858171
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
G
Plaur
plasminogen activator, urokinase receptor
decreases expression
ISO
Piroxicam results in decreased expression of PLAUR mRNA
CTD
PMID:21858171
NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595
G
Plk4
polo-like kinase 4
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of PLK4 mRNA]
CTD
PMID:21858171
NCBI chr 2:123,802,527...123,820,942
Ensembl chr 2:123,802,512...123,820,942
G
Plpp3
phospholipid phosphatase 3
decreases expression
ISO
Piroxicam results in decreased expression of PLPP3 mRNA
CTD
PMID:19192274
NCBI chr 5:119,927,085...120,002,206
Ensembl chr 5:119,927,085...120,002,205
G
Pls1
plastin 1
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of PLS1 mRNA]
CTD
PMID:21858171
NCBI chr 8:96,316,703...96,426,592
Ensembl chr 8:96,317,849...96,385,195
G
Plxnb2
plexin B2
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of PLXNB2 mRNA
CTD
PMID:21858171
NCBI chr 7:120,232,276...120,258,385
Ensembl chr 7:120,232,331...120,258,330
G
Pnn
pinin, desmosome associated protein
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of PNN mRNA]
CTD
PMID:21858171
NCBI chr 6:76,758,138...76,766,451
Ensembl chr 6:76,758,117...76,766,889
G
Pold3
DNA polymerase delta 3, accessory subunit
decreases expression
ISO
Piroxicam results in decreased expression of POLD3 mRNA
CTD
PMID:21858171
NCBI chr 1:154,417,893...154,456,687
Ensembl chr 1:154,418,084...154,456,665
G
Pole2
DNA polymerase epsilon 2, accessory subunit
increases expression multiple interactions
ISO
Piroxicam results in increased expression of POLE2 mRNA Cisplatin inhibits the reaction [Piroxicam results in increased expression of POLE2 mRNA]
CTD
PMID:21858171
NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305
G
Pole3
DNA polymerase epsilon 3, accessory subunit
decreases expression
ISO
Piroxicam results in decreased expression of POLE3 mRNA
CTD
PMID:21858171
NCBI chr 5:75,973,941...75,977,175
Ensembl chr 5:75,974,717...75,977,231 Ensembl chr 7:75,974,717...75,977,231
G
Polr3k
RNA polymerase III subunit K
decreases expression
ISO
Piroxicam results in decreased expression of POLR3K mRNA
CTD
PMID:21858171
NCBI chr 3:168,982,846...168,987,043
Ensembl chr 3:168,982,812...168,987,040
G
Pop7
POP7 homolog, ribonuclease P/MRP subunit
decreases expression
ISO
Piroxicam results in decreased expression of POP7 mRNA
CTD
PMID:21858171
NCBI chr12:19,189,384...19,190,425
Ensembl chr12:19,189,138...19,190,674
G
Ppm1b
protein phosphatase, Mg2+/Mn2+ dependent, 1B
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of PPM1B mRNA
CTD
PMID:21858171
NCBI chr 6:9,646,695...9,707,471
Ensembl chr 6:9,655,765...9,707,974
G
Ppp1cb
protein phosphatase 1 catalytic subunit beta
decreases expression
ISO
Piroxicam results in decreased expression of PPP1CB mRNA
CTD
PMID:21858171
NCBI chr 6:23,958,813...23,992,841
Ensembl chr 6:23,960,998...23,992,824
G
Ppp1r15a
protein phosphatase 1, regulatory subunit 15A
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of PPP1R15A mRNA]
CTD
PMID:21858171
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
G
Ppp2r1b
protein phosphatase 2 scaffold subunit A beta
decreases expression
ISO
Piroxicam results in decreased expression of PPP2R1B mRNA
CTD
PMID:21858171
NCBI chr 8:51,195,860...51,228,442
Ensembl chr 8:51,186,717...51,228,485
G
Ppp3ca
protein phosphatase 3 catalytic subunit alpha
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of PPP3CA mRNA
CTD
PMID:21858171
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
G
Ppp4r2
protein phosphatase 4, regulatory subunit 2
increases expression
ISO
Piroxicam results in increased expression of PPP4R2 mRNA
CTD
PMID:19192274
NCBI chr 4:133,454,555...133,495,486
Ensembl chr 4:133,454,555...133,495,486
G
Prc1
protein regulator of cytokinesis 1
decreases expression
ISO
Piroxicam results in decreased expression of PRC1 mRNA
CTD
PMID:21858171
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
G
Prdm4
PR/SET domain 4
decreases expression
ISO
Piroxicam results in decreased expression of PRDM4 mRNA
CTD
PMID:21858171
NCBI chr 7:17,953,832...17,980,489
Ensembl chr 7:17,954,019...17,980,489
G
Prkacb
protein kinase cAMP-activated catalytic subunit beta
decreases expression
ISO
Piroxicam results in decreased expression of PRKACB mRNA
CTD
PMID:21858171
NCBI chr 2:235,636,878...235,726,928
Ensembl chr 2:235,636,885...235,726,198
G
Prpf18
pre-mRNA processing factor 18
decreases expression
ISO
Piroxicam results in decreased expression of PRPF18 mRNA
CTD
PMID:21858171
NCBI chr17:73,630,560...73,661,210
Ensembl chr17:73,630,571...73,690,979
G
Prpf4b
pre-mRNA processing factor 4B
decreases expression
ISO
Piroxicam results in decreased expression of PRP4K mRNA
CTD
PMID:21858171
NCBI chr17:29,985,343...30,020,285
Ensembl chr17:29,985,343...30,019,625
G
Prps1
phosphoribosyl pyrophosphate synthetase 1
decreases expression
ISO
Piroxicam results in decreased expression of PRPS1 mRNA
CTD
PMID:21858171
NCBI chr X:104,132,139...104,154,191
Ensembl chr X:104,132,141...104,154,187
G
Psap
prosaposin
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of PSAP mRNA]
CTD
PMID:21858171
NCBI chr20:28,214,229...28,240,501
Ensembl chr20:28,214,271...28,240,498
G
Psat1
phosphoserine aminotransferase 1
decreases expression
ISO
Piroxicam results in decreased expression of PSAT1 mRNA
CTD
PMID:21858171
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
G
Psma2
proteasome 20S subunit alpha 2
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of PSMA2 mRNA Cisplatin promotes the reaction [Piroxicam results in decreased expression of PSMA2 mRNA]
CTD
PMID:21858171
NCBI chr17:50,554,536...50,564,923
Ensembl chr17:50,551,924...50,564,938
G
Psmc2
proteasome 26S subunit, ATPase 2
decreases expression
ISO
Piroxicam results in decreased expression of PSMC2 mRNA
CTD
PMID:21858171
NCBI chr 4:13,255,850...13,270,160
Ensembl chr 4:13,255,856...13,270,185
G
Psmc3ip
PSMC3 interacting protein
increases expression
ISO
Piroxicam results in increased expression of PSMC3IP mRNA
CTD
PMID:21858171
NCBI chr10:86,024,281...86,027,928
Ensembl chr10:86,023,950...86,027,423
G
Psmd12
proteasome 26S subunit, non-ATPase 12
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of PSMD12 mRNA Cisplatin affects the reaction [Piroxicam results in decreased expression of PSMD12 mRNA]
CTD
PMID:21858171
NCBI chr10:92,438,223...92,457,323
Ensembl chr10:92,438,298...92,457,287
G
Ptger4
prostaglandin E receptor 4
decreases expression
ISO
Piroxicam results in decreased expression of PTGER4 mRNA
CTD
PMID:21858171
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
G
Ptgs1
prostaglandin-endoperoxide synthase 1
decreases activity
EXP
Piroxicam results in decreased activity of PTGS1 protein
CTD
PMID:9258749
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
G
Ptgs2
prostaglandin-endoperoxide synthase 2
multiple interactions decreases expression decreases activity
ISO EXP
Piroxicam inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] Piroxicam results in decreased expression of PTGS2 mRNA Piroxicam results in decreased activity of PTGS2 protein [Hydrochloric Acid co-treated with Piroxicam] results in increased expression of PTGS2 mRNA; Piroxicam promotes the reaction [L 748706 results in decreased activity of PTGS2 protein] Piroxicam binds to and results in decreased activity of PTGS2 protein; Piroxicam inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
CTD
PMID:9258749 PMID:12925531 PMID:15309881 PMID:15878914 PMID:19147701 PMID:19192274 PMID:19931610 More...
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
G
Ptp4a1
protein tyrosine phosphatase 4A1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of PTP4A1 mRNA
CTD
PMID:21858171
NCBI chr 9:33,214,201...33,245,046
Ensembl chr 9:33,214,208...33,221,964
G
Ptp4a2
protein tyrosine phosphatase 4A2
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of PTP4A2 mRNA]
CTD
PMID:21858171
NCBI chr 5:142,165,405...142,192,412
Ensembl chr 5:142,165,700...142,191,899
G
Ptx3
pentraxin 3
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of PTX3 mRNA
CTD
PMID:21858171
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
G
Rab1a
RAB1A, member RAS oncogene family
decreases expression
ISO
Piroxicam results in decreased expression of RAB1A mRNA
CTD
PMID:21858171
NCBI chr14:94,422,219...94,448,799
Ensembl chr14:94,415,275...94,448,248
G
Rab2a
RAB2A, member RAS oncogene family
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of RAB2A mRNA
CTD
PMID:21858171
NCBI chr 5:21,676,017...21,740,035
Ensembl chr 5:21,676,129...21,739,899
G
Rab7a
RAB7A, member RAS oncogene family
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of RAB7A mRNA
CTD
PMID:21858171
NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889
G
Rab8a
RAB8A, member RAS oncogene family
increases expression
ISO
Piroxicam results in increased expression of RAB8A mRNA
CTD
PMID:21858171
NCBI chr16:17,654,027...17,675,385
Ensembl chr16:17,654,034...17,675,678
G
Rabep1
rabaptin, RAB GTPase binding effector protein 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of RABEP1 mRNA
CTD
PMID:21858171
NCBI chr10:55,566,156...55,667,595
Ensembl chr10:55,566,185...55,665,973
G
Racgap1
Rac GTPase-activating protein 1
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of RACGAP1 mRNA]
CTD
PMID:21858171
NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831
G
Rad1
RAD1 checkpoint DNA exonuclease
decreases expression
ISO
Piroxicam results in decreased expression of RAD1 mRNA
CTD
PMID:21858171
NCBI chr 2:59,461,597...59,469,707
Ensembl chr 2:59,461,607...59,469,689
G
Rad17
RAD17 checkpoint clamp loader component
increases expression
ISO
Piroxicam results in increased expression of RAD17 mRNA
CTD
PMID:21858171
NCBI chr 2:31,764,260...31,794,542
Ensembl chr 2:31,764,261...31,794,072
G
Rad50
RAD50 double strand break repair protein
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of RAD50 mRNA]
CTD
PMID:21858171
NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396
G
Rad51ap1
RAD51 associated protein 1
decreases expression
ISO
Piroxicam results in decreased expression of RAD51AP1 mRNA
CTD
PMID:21858171
NCBI chr 4:159,759,454...159,772,473
Ensembl chr 4:159,759,459...159,772,524
G
Ranbp1
RAN binding protein 1
decreases expression
ISO
Piroxicam results in decreased expression of RANBP1 mRNA
CTD
PMID:21858171
NCBI chr11:82,742,603...82,750,836
Ensembl chr11:82,742,600...82,750,838
G
Ranbp2
RAN binding protein 2
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of RANBP2 mRNA
CTD
PMID:21858171
NCBI chr20:26,442,156...26,493,481
Ensembl chr20:26,442,217...26,493,481
G
Rb1
RB transcriptional corepressor 1
decreases expression
ISO
Piroxicam results in decreased expression of RB1 mRNA
CTD
PMID:21858171
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
G
Rbbp4
RB binding protein 4, chromatin remodeling factor
decreases expression
ISO
Piroxicam results in decreased expression of RBBP4 mRNA
CTD
PMID:21858171
NCBI chr 5:141,655,863...141,675,157
Ensembl chr 5:141,638,421...141,675,284 Ensembl chr 2:141,638,421...141,675,284
G
Rbm25
RNA binding motif protein 25
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of RBM25 mRNA]
CTD
PMID:21858171
NCBI chr 6:103,271,775...103,319,090
Ensembl chr 6:103,271,801...103,317,854
G
Rbx1
ring-box 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of RBX1 mRNA
CTD
PMID:21858171
NCBI chr 7:112,976,863...113,001,051
Ensembl chr 7:112,990,835...113,001,051
G
Rdh11
retinol dehydrogenase 11
multiple interactions
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of RDH11 mRNA]
CTD
PMID:21858171
NCBI chr 6:97,979,377...97,995,252
Ensembl chr 6:97,979,378...97,995,252
G
Recql
RecQ like helicase
decreases expression
ISO
Piroxicam results in decreased expression of RECQL mRNA
CTD
PMID:21858171
NCBI chr 4:175,308,337...175,332,965
Ensembl chr 4:175,304,117...175,332,945
G
Reep5
receptor accessory protein 5
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of REEP5 mRNA Cisplatin inhibits the reaction [Piroxicam results in decreased expression of REEP5 mRNA]
CTD
PMID:21858171
NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509
G
Rexo4
REX4 homolog, 3'-5' exonuclease
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of REXO4 mRNA
CTD
PMID:21858171
NCBI chr 3:10,280,654...10,291,003
Ensembl chr 3:10,280,654...10,290,996
G
Rfc2
replication factor C subunit 2
decreases expression
ISO
Piroxicam results in decreased expression of RFC2 mRNA
CTD
PMID:21858171
NCBI chr12:22,120,449...22,133,576
Ensembl chr12:22,120,010...22,133,557
G
Rfc3
replication factor C subunit 3
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of RFC3 mRNA]
CTD
PMID:21858171
NCBI chr12:1,000,987...1,011,778
Ensembl chr12:1,000,994...1,011,778
G
Rfc5
replication factor C subunit 5
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of RFC5 mRNA]
CTD
PMID:21858171
NCBI chr12:39,207,484...39,217,041
Ensembl chr12:39,207,484...39,217,312
G
Rgs4
regulator of G-protein signaling 4
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of RGS4 mRNA]
CTD
PMID:19192274 PMID:21858171
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
G
Rig1
RNA sensor RIG-1
decreases expression
ISO
Piroxicam results in decreased expression of RIGI mRNA
CTD
PMID:19192274
NCBI chr 5:55,321,351...55,369,947
Ensembl chr 5:55,321,235...55,370,819
G
Ripk2
receptor-interacting serine-threonine kinase 2
decreases expression
ISO
Piroxicam results in decreased expression of RIPK2 mRNA
CTD
PMID:19192274
NCBI chr 5:29,630,806...29,662,804
Ensembl chr 5:29,631,570...29,662,657
G
Rnaseh1
ribonuclease H1
increases expression
ISO
Piroxicam results in increased expression of RNASEH1 mRNA
CTD
PMID:21858171
NCBI chr 6:45,282,849...45,292,258
Ensembl chr 6:45,282,854...45,292,236
G
Rnd3
Rho family GTPase 3
increases expression
ISO
Piroxicam results in increased expression of RND3 mRNA
CTD
PMID:21858171
NCBI chr 3:35,571,929...35,589,283
Ensembl chr 3:35,571,143...35,589,327
G
Rnf139
ring finger protein 139
decreases expression
ISO
Piroxicam results in decreased expression of RNF139 mRNA
CTD
PMID:21858171
NCBI chr 7:90,439,726...90,450,911
Ensembl chr 7:90,436,621...90,488,009
G
Rnf19b
ring finger protein 19B
decreases expression
ISO
Piroxicam results in decreased expression of RNF19B mRNA
CTD
PMID:19192274
NCBI chr 5:141,406,085...141,431,376
Ensembl chr 5:141,406,118...141,431,380
G
Rpa2
replication protein A2
decreases expression
ISO
Piroxicam results in decreased expression of RPA2 mRNA
CTD
PMID:21858171
NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350
G
Rpia
ribose 5-phosphate isomerase A
decreases expression
ISO
Piroxicam results in decreased expression of RPIA mRNA
CTD
PMID:21858171
NCBI chr 4:102,723,712...102,749,374
Ensembl chr 4:102,723,712...102,749,355
G
Rrm2
ribonucleotide reductase regulatory subunit M2
decreases expression
ISO
Piroxicam results in decreased expression of RRM2 mRNA
CTD
PMID:21858171
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
G
Rsad2
radical S-adenosyl methionine domain containing 2
decreases expression
ISO
Piroxicam results in decreased expression of RSAD2 mRNA
CTD
PMID:19192274
NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699
G
Rsu1
Ras suppressor protein 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of RSU1 mRNA
CTD
PMID:21858171
NCBI chr17:76,128,774...76,377,515
Ensembl chr17:76,188,812...76,377,454
G
RT1-A2
RT1 class Ia, locus A2
decreases expression
ISO
Piroxicam results in decreased expression of HLA-E mRNA
CTD
PMID:21858171
NCBI chr20:4,870,939...4,910,183
G
RT1-CE16
RT1 class I, locus CE16
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of HLA-A mRNA
CTD
PMID:21858171
NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563
G
RT1-DMb
RT1 class II, locus DMb
affects expression
ISO
Piroxicam affects the expression of HLA-DMB mRNA
CTD
PMID:25811541
NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340
G
RT1-M3-1
RT1 class Ib, locus M3, gene 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of HLA-G mRNA
CTD
PMID:21858171
NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117
G
Rtn3
reticulon 3
increases expression
ISO
Piroxicam results in increased expression of RTN3 mRNA
CTD
PMID:21858171
NCBI chr 1:204,612,675...204,669,212
Ensembl chr 1:204,612,675...204,669,275
G
Rybp
RING1 and YY1 binding protein
decreases expression
ISO
Piroxicam results in decreased expression of RYBP mRNA
CTD
PMID:21858171
NCBI chr 4:132,876,260...132,928,328
Ensembl chr 4:132,876,361...132,928,316
G
Sap30
Sin3A associated protein 30
decreases expression
ISO
Piroxicam results in decreased expression of SAP30 mRNA
CTD
PMID:21858171
NCBI chr16:32,747,777...32,753,114
Ensembl chr16:32,747,734...32,753,112
G
Sar1a
secretion associated, Ras related GTPase 1A
decreases expression
ISO
Piroxicam results in decreased expression of SAR1A mRNA
CTD
PMID:21858171
NCBI chr20:29,623,529...29,635,935
Ensembl chr20:29,623,553...29,635,935
G
Sars1
seryl-tRNA synthetase 1
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of SARS1 mRNA Cisplatin inhibits the reaction [Piroxicam results in decreased expression of SARS1 mRNA]
CTD
PMID:21858171
NCBI chr 2:196,065,543...196,081,240
Ensembl chr 2:196,065,430...196,081,277
G
Sat1
spermidine/spermine N1-acetyl transferase 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of SAT1 mRNA
CTD
PMID:21858171
NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813
G
Sav1
salvador family WW domain containing protein 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of SAV1 mRNA
CTD
PMID:21858171
NCBI chr 6:88,478,536...88,500,121
Ensembl chr 6:88,478,539...88,499,968
G
Scd
stearoyl-CoA desaturase
decreases expression
ISO
Piroxicam results in decreased expression of SCD mRNA
CTD
PMID:21858171
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
G
Scn5a
sodium voltage-gated channel alpha subunit 5
decreases activity
ISO
Piroxicam results in decreased activity of SCN5A protein
CTD
PMID:33617802
NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769
G
Sec31a
SEC31 homolog A, COPII coat complex component
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of SEC31A mRNA
CTD
PMID:21858171
NCBI chr14:9,214,324...9,269,281
Ensembl chr14:9,214,349...9,269,273
G
Sel1l
SEL1L adaptor subunit of SYVN1 ubiquitin ligase
decreases expression
ISO
Piroxicam results in decreased expression of SEL1L mRNA
CTD
PMID:21858171
NCBI chr 6:110,735,450...110,779,695
Ensembl chr 6:110,735,450...110,779,648
G
Selenow
selenoprotein W
decreases expression
ISO
Piroxicam results in decreased expression of SELENOW mRNA
CTD
PMID:21858171
NCBI chr 1:76,599,441...76,604,514
Ensembl chr 1:76,598,779...76,604,724 Ensembl chr 1:76,598,779...76,604,724
G
Sell
selectin L
affects expression
ISO
Piroxicam affects the expression of SELL protein
CTD
PMID:12147693
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
G
Sephs1
selenophosphate synthetase 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of SEPHS1 mRNA
CTD
PMID:21858171
NCBI chr17:73,354,435...73,382,803
Ensembl chr17:73,356,530...73,382,593
G
Sertad2
SERTA domain containing 2
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of SERTAD2 mRNA
CTD
PMID:21858171
NCBI chr14:94,733,637...94,838,200
Ensembl chr14:94,733,579...94,838,313
G
Sesn1
sestrin 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of SESN1 mRNA
CTD
PMID:21858171
NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697
G
Sf3a3
splicing factor 3a, subunit 3
decreases expression
ISO
Piroxicam results in decreased expression of SF3A3 mRNA
CTD
PMID:21858171
NCBI chr 5:136,967,713...136,987,345
Ensembl chr 5:136,967,691...136,987,361
G
Sh2b3
SH2B adaptor protein 3
increases expression
ISO
Piroxicam results in increased expression of SH2B3 mRNA
CTD
PMID:21858171
NCBI chr12:34,731,934...34,753,617
Ensembl chr12:34,731,911...34,753,616
G
Sh3glb1
SH3 domain -containing GRB2-like endophilin B1
decreases expression
ISO
Piroxicam results in decreased expression of SH3GLB1 mRNA
CTD
PMID:21858171
NCBI chr 2:233,750,838...233,784,817
Ensembl chr 2:233,750,838...233,784,784
G
Shcbp1
SHC binding and spindle associated 1
multiple interactions increases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in increased expression of SHCBP1 mRNA]
CTD
PMID:21858171
NCBI chr16:84,672,277...84,703,843
Ensembl chr16:84,672,321...84,703,844
G
Sinhcaf
SIN3-HDAC complex associated factor
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of SINHCAF mRNA
CTD
PMID:21858171
NCBI chr 4:181,888,301...181,913,294
Ensembl chr 4:181,888,312...181,910,276
G
Siva1
SIVA1, apoptosis-inducing factor
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of SIVA1 mRNA]
CTD
PMID:21858171
NCBI chr 6:131,705,323...131,709,697
Ensembl chr 6:131,705,323...131,709,690
G
Skp1
S-phase kinase-associated protein 1
decreases expression
ISO
Piroxicam results in decreased expression of SKP1 mRNA
CTD
PMID:21858171
NCBI chr10:36,401,987...36,417,066
Ensembl chr10:36,402,153...36,417,388
G
Skp2
S-phase kinase associated protein 2
decreases expression
ISO
Piroxicam results in decreased expression of SKP2 mRNA
CTD
PMID:21858171
NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338
G
Slc16a1
solute carrier family 16 member 1
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of SLC16A1 mRNA]
CTD
PMID:21858171
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
G
Slc22a2
solute carrier family 22 member 2
decreases activity
ISO
Piroxicam results in decreased activity of SLC22A2 protein
CTD
PMID:12388633
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
G
Slc22a25
solute carrier family 22, member 25
decreases activity
ISO
Piroxicam results in decreased activity of SLC22A9 protein
CTD
PMID:12388633
NCBI chr 1:205,338,698...205,498,486
Ensembl chr 1:205,338,699...205,433,085
G
Slc22a6
solute carrier family 22 member 6
decreases activity multiple interactions
ISO EXP
Piroxicam results in decreased activity of SLC22A6 protein Piroxicam inhibits the reaction [SLC22A6 protein results in increased uptake of ochratoxin A]
CTD
PMID:10336520 PMID:12388633
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
G
Slc22a7
solute carrier family 22 member 7
decreases activity
ISO
Piroxicam results in decreased activity of SLC22A7 protein
CTD
PMID:12388633
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
G
Slc22a8
solute carrier family 22 member 8
multiple interactions
EXP
Piroxicam inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]
CTD
PMID:10224140
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
G
Slc25a12
solute carrier family 25 member 12
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of SLC25A12 mRNA]
CTD
PMID:21858171
NCBI chr 3:56,097,166...56,191,841
Ensembl chr 3:56,097,269...56,192,100
G
Slc25a13
solute carrier family 25 member 13
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of SLC25A13 mRNA]
CTD
PMID:21858171
NCBI chr 4:34,179,224...34,361,912
Ensembl chr 4:34,179,224...34,361,902
G
Slc3a2
solute carrier family 3 member 2
decreases expression
ISO
Piroxicam results in decreased expression of SLC3A2 mRNA
CTD
PMID:21858171
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
G
Slc5a3
solute carrier family 5 member 3
increases expression
ISO
Piroxicam results in increased expression of SLC5A3 mRNA
CTD
PMID:21858171
NCBI chr11:31,313,847...31,316,293
Ensembl chr11:31,295,476...31,318,883
G
Slc6a15
solute carrier family 6 member 15
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of SLC6A15 mRNA]
CTD
PMID:21858171
NCBI chr 7:38,553,055...38,607,239
Ensembl chr 7:38,553,196...38,607,239
G
Slc6a8
solute carrier family 6 member 8
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of SLC6A8 mRNA
CTD
PMID:21858171
NCBI chr X:151,384,675...151,393,979
Ensembl chr X:151,384,675...151,393,979
G
Slc7a11
solute carrier family 7 member 11
decreases expression
ISO
Piroxicam results in decreased expression of SLC7A11 mRNA
CTD
PMID:19192274
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
G
Slc7a5
solute carrier family 7 member 5
decreases expression
ISO
Piroxicam results in decreased expression of SLC7A5 mRNA
CTD
PMID:21858171
NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823
G
Slc7a8
solute carrier family 7 member 8
increases expression
ISO
Piroxicam results in increased expression of SLC7A8 mRNA
CTD
PMID:19192274
NCBI chr15:28,183,013...28,242,717
Ensembl chr15:28,183,015...28,242,717
G
Slit2
slit guidance ligand 2
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of SLIT2 mRNA
CTD
PMID:21858171
NCBI chr14:62,616,337...62,955,934
Ensembl chr14:62,617,067...62,955,948
G
Smarca5
SNF2 related chromatin remodeling ATPase 5
decreases expression
ISO
Piroxicam results in decreased expression of SMARCA5 mRNA
CTD
PMID:21858171
NCBI chr19:27,271,918...27,304,594
Ensembl chr19:27,271,148...27,304,594
G
Smarce1
SWI/SNF related BAF chromatin remodeling complex subunit E1
decreases expression
ISO
Piroxicam results in decreased expression of SMARCE1 mRNA
CTD
PMID:21858171
NCBI chr10:84,159,270...84,180,547
Ensembl chr10:84,159,275...84,179,989
G
Smc2
structural maintenance of chromosomes 2
decreases expression
ISO
Piroxicam results in decreased expression of SMC2 mRNA
CTD
PMID:21858171
NCBI chr 5:66,806,882...66,853,478
Ensembl chr 5:66,807,011...66,853,242
G
Smc3
structural maintenance of chromosomes 3
decreases expression
ISO
Piroxicam results in decreased expression of SMC3 mRNA
CTD
PMID:21858171
NCBI chr 1:252,601,422...252,644,522
Ensembl chr 1:252,601,753...252,644,522
G
Sms
spermine synthase
decreases expression
ISO
Piroxicam results in decreased expression of SMS mRNA
CTD
PMID:19192274
NCBI chr X:37,516,949...37,572,657
Ensembl chr X:37,516,931...37,570,822 Ensembl chr 3:37,516,931...37,570,822
G
Snrnp40
small nuclear ribonucleoprotein U5 subunit 40
decreases expression
ISO
Piroxicam results in decreased expression of SNRNP40 mRNA
CTD
PMID:21858171
NCBI chr 5:142,700,632...142,733,776
Ensembl chr 5:142,700,534...142,733,776
G
Snrpa
small nuclear ribonucleoprotein polypeptide A
decreases expression
ISO
Piroxicam results in decreased expression of SNRPA mRNA
CTD
PMID:21858171
NCBI chr 1:82,481,770...82,490,540
Ensembl chr 1:82,481,770...82,490,538
G
Snrpa1
small nuclear ribonucleoprotein polypeptide A'
increases expression
ISO
Piroxicam results in increased expression of SNRPA1 mRNA
CTD
PMID:21858171
NCBI chr 1:119,641,402...119,654,653
Ensembl chr 1:119,638,481...119,654,653
G
Snrpd1
small nuclear ribonucleoprotein D1 polypeptide
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of SNRPD1 mRNA
CTD
PMID:21858171
NCBI chr18:1,696,838...1,707,400
Ensembl chr18:1,696,852...1,708,256
G
Snx5
sorting nexin 5
decreases expression
ISO
Piroxicam results in decreased expression of SNX5 mRNA
CTD
PMID:21858171
NCBI chr 3:131,621,875...131,641,127
Ensembl chr 3:131,621,880...131,641,192
G
Sod2
superoxide dismutase 2
decreases expression
ISO
Piroxicam results in decreased expression of SOD2 mRNA
CTD
PMID:19192274
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
G
Spag5
sperm associated antigen 5
decreases expression
ISO
Piroxicam results in decreased expression of SPAG5 mRNA
CTD
PMID:21858171
NCBI chr10:63,198,717...63,216,746
Ensembl chr10:63,198,768...63,216,745
G
Sparc
secreted protein acidic and cysteine rich
decreases expression
ISO
Piroxicam results in decreased expression of SPARC mRNA
CTD
PMID:21858171
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
G
Spcs2
signal peptidase complex subunit 2
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of SPCS2 mRNA Cisplatin inhibits the reaction [Piroxicam results in decreased expression of SPCS2 mRNA]
CTD
PMID:21858171
NCBI chr 1:154,163,724...154,183,152
Ensembl chr 1:154,163,724...154,183,186
G
Spdl1
spindle apparatus coiled-coil protein 1
increases expression
ISO
Piroxicam results in increased expression of SPDL1 mRNA
CTD
PMID:21858171
NCBI chr10:19,269,125...19,294,213
Ensembl chr10:19,269,127...19,294,127
G
Spp1
secreted phosphoprotein 1
decreases expression
ISO
Piroxicam results in decreased expression of SPP1 mRNA
CTD
PMID:21858171
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
G
Sptlc2
serine palmitoyltransferase, long chain base subunit 2
decreases expression
ISO
Piroxicam results in decreased expression of SPTLC2 mRNA
CTD
PMID:21858171
NCBI chr 6:106,948,682...107,031,532
Ensembl chr 6:106,950,949...107,031,542
G
Sqstm1
sequestosome 1
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of SQSTM1 mRNA]
CTD
PMID:21858171
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
G
Srsf1
serine and arginine rich splicing factor 1
increases expression
ISO
Piroxicam results in increased expression of SRSF1 mRNA
CTD
PMID:21858171
NCBI chr10:72,838,926...72,859,066
Ensembl chr10:72,839,274...72,845,336
G
Srsf10
serine and arginine rich splicing factor 10
decreases expression
ISO
Piroxicam results in decreased expression of SRSF10 mRNA
CTD
PMID:21858171
NCBI chr 5:148,088,759...148,102,964
Ensembl chr 5:148,088,823...148,101,768
G
Srsf2
serine and arginine rich splicing factor 2
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of SRSF2 mRNA Cisplatin inhibits the reaction [Piroxicam results in decreased expression of SRSF2 mRNA]
CTD
PMID:21858171
NCBI chr10:102,052,158...102,055,365
Ensembl chr10:102,052,314...102,055,338
G
Srsf3
serine and arginine rich splicing factor 3
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of SRSF3 mRNA]
CTD
PMID:21858171
NCBI chr20:7,091,928...7,101,860
Ensembl chr20:7,091,910...7,101,078
G
Srsf6
serine and arginine rich splicing factor 6
decreases expression
ISO
Piroxicam results in decreased expression of SRSF6 mRNA
CTD
PMID:21858171
NCBI chr 3:151,589,546...151,594,869
Ensembl chr 3:151,589,535...151,594,860
G
Srsf7
serine and arginine rich splicing factor 7
decreases expression
ISO
Piroxicam results in decreased expression of SRSF7 mRNA
CTD
PMID:21858171
NCBI chr 6:14,811,775...14,818,968
Ensembl chr 6:14,811,808...14,818,965
G
Ssr3
signal sequence receptor subunit 3
decreases expression
ISO
Piroxicam results in decreased expression of SSR3 mRNA
CTD
PMID:21858171
NCBI chr 2:149,605,005...149,625,069
Ensembl chr 2:149,605,005...149,625,132
G
Ssx2ip
SSX family member 2 interacting protein
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of SSX2IP mRNA]
CTD
PMID:21858171
NCBI chr 2:235,298,012...235,330,750
Ensembl chr 2:235,298,088...235,330,745
G
Stat3
signal transducer and activator of transcription 3
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of STAT3 mRNA
CTD
PMID:21858171
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
G
Stat4
signal transducer and activator of transcription 4
decreases expression
ISO
Piroxicam results in decreased expression of STAT4 mRNA
CTD
PMID:19192274
NCBI chr 9:49,472,660...49,588,540
Ensembl chr 9:49,419,340...49,588,540
G
Stc2
stanniocalcin 2
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of STC2 mRNA
CTD
PMID:21858171
NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973
G
Stip1
stress-induced phosphoprotein 1
increases expression
ISO
Piroxicam results in increased expression of STIP1 mRNA
CTD
PMID:21858171
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
G
Stk39
serine threonine kinase 39
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of STK39 mRNA
CTD
PMID:21858171
NCBI chr 3:52,913,583...53,179,060
Ensembl chr 3:52,913,585...53,179,060
G
Stmn1
stathmin 1
decreases expression
ISO
Piroxicam results in decreased expression of STMN1 mRNA
CTD
PMID:21858171
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
G
Sts
steroid sulfatase
increases expression
ISO
Piroxicam results in increased expression of STS mRNA
CTD
PMID:19192274
NCBI chr X:42,225,131...42,233,403
Ensembl chr X:42,225,372...42,233,402
G
Sucla2
succinate-CoA ligase ADP-forming subunit beta
decreases expression
ISO
Piroxicam results in decreased expression of SUCLA2 mRNA
CTD
PMID:21858171
NCBI chr15:48,752,356...48,805,495
Ensembl chr15:48,752,312...48,805,138
G
Sult1a1
sulfotransferase family 1A member 1
decreases activity
ISO
Piroxicam results in decreased activity of SULT1A1 protein
CTD
PMID:17073578
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
G
Syncrip
synaptotagmin binding, cytoplasmic RNA interacting protein
increases expression
ISO
Piroxicam results in increased expression of SYNCRIP mRNA
CTD
PMID:21858171
NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515
G
Tcf3
transcription factor 3
decreases expression
ISO
Piroxicam results in decreased expression of TCF3 mRNA
CTD
PMID:21858171
NCBI chr 7:9,280,571...9,302,315
Ensembl chr 7:9,280,571...9,302,314
G
Tdg
thymine-DNA glycosylase
decreases expression
ISO
Piroxicam results in decreased expression of TDG mRNA
CTD
PMID:21858171
NCBI chr 7:21,077,853...21,097,617
Ensembl chr 7:21,077,853...21,097,567
G
Terf2
telomeric repeat binding factor 2
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of TERF2 mRNA]
CTD
PMID:21858171
NCBI chr19:34,976,963...35,005,813
Ensembl chr19:34,977,471...35,005,819
G
Tfam
transcription factor A, mitochondrial
decreases expression
ISO
Piroxicam results in decreased expression of TFAM mRNA
CTD
PMID:21858171
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
G
Tgfa
transforming growth factor alpha
multiple interactions
EXP
Piroxicam promotes the reaction [Hydrochloric Acid results in increased expression of TGFA protein]
CTD
PMID:15309881
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
G
Tgif1
TGFB-induced factor homeobox 1
decreases expression
ISO
Piroxicam results in decreased expression of TGIF1 mRNA
CTD
PMID:21858171
NCBI chr 9:110,748,094...110,757,714
Ensembl chr 9:110,720,921...110,757,802
G
Tgm2
transglutaminase 2
decreases expression
ISO
Piroxicam results in decreased expression of TGM2 mRNA
CTD
PMID:21858171
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
G
Thbs2
thrombospondin 2
increases expression
ISO
Piroxicam results in increased expression of THBS2 mRNA
CTD
PMID:19192274
NCBI chr 1:55,670,394...55,699,789
Ensembl chr 1:55,670,394...55,699,789
G
Thoc2
THO complex subunit 2
increases expression
ISO
Piroxicam results in increased expression of THOC2 mRNA
CTD
PMID:21858171
NCBI chr X:120,634,966...120,749,569
Ensembl chr X:120,634,968...120,749,513
G
Timm10
translocase of inner mitochondrial membrane 10
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of TIMM10 mRNA
CTD
PMID:21858171
NCBI chr 3:69,908,397...69,911,943
Ensembl chr 3:69,908,456...69,911,940
G
Timm13
translocase of inner mitochondrial membrane 13
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of TIMM13 mRNA
CTD
PMID:21858171
NCBI chr 7:8,809,069...8,810,172
Ensembl chr 7:8,809,058...8,809,910
G
Timm17a
translocase of inner mitochondrial membrane 17A
decreases expression
ISO
Piroxicam results in decreased expression of TIMM17A mRNA
CTD
PMID:21858171
NCBI chr13:46,731,117...46,742,604
Ensembl chr13:46,730,660...46,742,655
G
Timm23
translocase of inner mitochondrial membrane 23
increases expression
ISO
Piroxicam results in increased expression of TIMM23 mRNA
CTD
PMID:21858171
NCBI chr16:7,410,308...7,436,392
Ensembl chr16:7,409,688...7,436,379 Ensembl chr 3:7,409,688...7,436,379 Ensembl chr 6:7,409,688...7,436,379
G
Tipin
timeless interacting protein
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of TIPIN mRNA]
CTD
PMID:21858171
NCBI chr 8:64,780,813...64,801,358
Ensembl chr 8:64,780,828...64,801,352 Ensembl chr 9:64,780,828...64,801,352
G
Tjp2
tight junction protein 2
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of TJP2 mRNA]
CTD
PMID:21858171
NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295
G
Tk1
thymidine kinase 1
decreases expression
ISO
Piroxicam results in decreased expression of TK1 mRNA
CTD
PMID:21858171
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
G
Tlr2
toll-like receptor 2
decreases expression
ISO
Piroxicam results in decreased expression of TLR2 mRNA
CTD
PMID:19192274
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
G
Tm4sf1
transmembrane 4 L six family member 1
decreases expression
ISO
Piroxicam results in decreased expression of TM4SF1 mRNA
CTD
PMID:21858171
NCBI chr 2:141,456,950...141,466,146
Ensembl chr 2:141,453,310...141,466,146
G
Tmed7
transmembrane p24 trafficking protein 7
increases expression
ISO
Piroxicam results in increased expression of TMED7 mRNA
CTD
PMID:21858171
NCBI chr18:39,318,564...39,325,640
Ensembl chr18:39,297,351...39,325,640
G
Tmem158
transmembrane protein 158
decreases expression
ISO
Piroxicam results in decreased expression of TMEM158 mRNA
CTD
PMID:21858171
NCBI chr 8:122,913,675...122,914,673
Ensembl chr 8:122,913,675...122,914,673
G
Tmem43
transmembrane protein 43
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of TMEM43 mRNA
CTD
PMID:21858171
NCBI chr 4:123,977,680...123,992,823
Ensembl chr 4:123,977,625...123,992,825
G
Tmpo
thymopoietin
multiple interactions increases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in increased expression of TMPO mRNA]
CTD
PMID:21858171
NCBI chr 7:25,642,752...25,667,756
Ensembl chr 7:25,586,725...25,667,727
G
Tmx1
thioredoxin-related transmembrane protein 1
decreases expression
ISO
Piroxicam results in decreased expression of TMX1 mRNA
CTD
PMID:21858171
NCBI chr 6:88,960,691...88,971,744
Ensembl chr 6:88,960,695...88,971,301
G
Tnf
tumor necrosis factor
multiple interactions
ISO
Piroxicam inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] [Piroxicam co-treated with Lipopolysaccharides] results in increased secretion of TNF protein
CTD
PMID:10328874 PMID:17328244
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Topbp1
DNA topoisomerase II binding protein 1
decreases expression
ISO
Piroxicam results in decreased expression of TOPBP1 mRNA
CTD
PMID:21858171
NCBI chr 8:103,887,805...103,931,662
Ensembl chr 8:103,887,865...103,931,674
G
Tp53
tumor protein p53
multiple interactions
ISO
Piroxicam promotes the reaction [Cisplatin results in increased expression of TP53 protein]
CTD
PMID:21858171
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tra2a
transformer 2 alpha
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of TRA2A mRNA
CTD
PMID:21858171
NCBI chr 4:78,220,838...78,239,737
Ensembl chr 4:78,220,883...78,239,712
G
Traf3ip2
Traf3 interacting protein 2
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of TRAF3IP2 mRNA
CTD
PMID:21858171
NCBI chr20:43,011,405...43,054,654
Ensembl chr20:43,011,450...43,054,667
G
Trappc4
trafficking protein particle complex subunit 4
decreases expression
ISO
Piroxicam results in decreased expression of TRAPPC4 mRNA
CTD
PMID:21858171
NCBI chr 8:44,729,458...44,733,285
Ensembl chr 8:44,725,331...44,733,491
G
Trhde
thyrotropin-releasing hormone degrading enzyme
decreases expression multiple interactions
ISO
Piroxicam results in decreased expression of TRHDE mRNA Cisplatin inhibits the reaction [Piroxicam results in decreased expression of TRHDE mRNA]
CTD
PMID:21858171
NCBI chr 7:49,943,271...50,350,613
Ensembl chr 7:49,945,766...50,367,371
G
Trib3
tribbles pseudokinase 3
decreases expression
ISO
Piroxicam results in decreased expression of TRIB3 mRNA
CTD
PMID:21858171
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
G
Trim28
tripartite motif-containing 28
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of TRIM28 mRNA
CTD
PMID:21858171
NCBI chr 1:73,652,441...73,659,388
Ensembl chr 1:73,652,709...73,659,380
G
Tsc22d1
TSC22 domain family, member 1
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of TSC22D1 mRNA
CTD
PMID:21858171
NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958
G
Tspan6
tetraspanin 6
decreases expression
ISO
Piroxicam results in decreased expression of TSPAN6 mRNA
CTD
PMID:21858171
NCBI chr X:97,092,394...97,099,659
Ensembl chr X:97,092,388...97,099,309
G
Ttc3
tetratricopeptide repeat domain 3
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of TTC3 mRNA
CTD
PMID:21858171
NCBI chr11:33,689,119...33,788,976
Ensembl chr11:33,688,952...33,788,975
G
Ttk
Ttk protein kinase
multiple interactions decreases expression
ISO
Cisplatin promotes the reaction [Piroxicam results in decreased expression of TTK mRNA]
CTD
PMID:21858171
NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651
G
Tuba1a
tubulin, alpha 1A
decreases expression
ISO
Piroxicam results in decreased expression of TUBA1A mRNA
CTD
PMID:21858171
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
G
Txndc9
thioredoxin domain containing 9
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of TXNDC9 mRNA]
CTD
PMID:21858171
NCBI chr 9:40,211,818...40,221,953
Ensembl chr 9:40,211,412...40,384,279 Ensembl chr 9:40,211,412...40,384,279
G
Txnip
thioredoxin interacting protein
multiple interactions increases expression decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of TXNIP mRNA] Piroxicam results in increased expression of TXNIP mRNA
CTD
PMID:19192274 PMID:21858171
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
G
Ube2a
ubiquitin-conjugating enzyme E2A
decreases expression
ISO
Piroxicam results in decreased expression of UBE2A mRNA
CTD
PMID:21858171
NCBI chr X:116,114,339...116,125,076
Ensembl chr X:116,113,875...116,125,070
G
Ube2b
ubiquitin-conjugating enzyme E2B
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of UBE2B mRNA]
CTD
PMID:21858171
NCBI chr10:36,248,434...36,263,379
Ensembl chr10:36,248,438...36,264,665
G
Ube2l3
ubiquitin-conjugating enzyme E2L 3
increases expression
ISO
Piroxicam results in increased expression of UBE2L3 mRNA
CTD
PMID:21858171
NCBI chr11:83,797,722...83,838,862
Ensembl chr11:83,797,722...83,838,862
G
Ube2n
ubiquitin-conjugating enzyme E2N
multiple interactions decreases expression
ISO
Cisplatin affects the reaction [Piroxicam results in decreased expression of UBE2N mRNA]
CTD
PMID:21858171
NCBI chr 7:30,154,330...30,184,373
Ensembl chr 7:30,154,616...30,184,355
G
Ubr7
ubiquitin protein ligase E3 component n-recognin 7
decreases expression
ISO
Piroxicam results in decreased expression of UBR7 mRNA
CTD
PMID:21858171
NCBI chr 6:121,898,613...121,918,480
Ensembl chr 6:121,898,623...121,918,477
G
Uchl5
ubiquitin C-terminal hydrolase L5
decreases expression
ISO
Piroxicam results in decreased expression of UCHL5 mRNA
CTD
PMID:21858171
NCBI chr13:55,520,722...55,556,503
Ensembl chr13:55,520,729...55,556,502
G
Ung
uracil-DNA glycosylase
decreases expression
ISO
Piroxicam results in decreased expression of UNG mRNA
CTD
PMID:21858171
NCBI chr12:42,485,276...42,494,217
Ensembl chr12:42,485,276...42,494,206
G
Usp1
ubiquitin specific peptidase 1
decreases expression
ISO
Piroxicam results in decreased expression of USP1 mRNA
CTD
PMID:21858171
NCBI chr 5:113,587,564...113,598,934
Ensembl chr 5:113,587,564...113,598,932
G
Usp16
ubiquitin specific peptidase 16
increases expression
ISO
Piroxicam results in increased expression of USP16 mRNA
CTD
PMID:21858171
NCBI chr11:26,681,359...26,711,313
Ensembl chr11:26,681,414...26,710,539
G
Usp46
ubiquitin specific peptidase 46
decreases expression
ISO
Piroxicam results in decreased expression of USP46 mRNA
CTD
PMID:21858171
NCBI chr14:34,150,055...34,219,227
Ensembl chr14:34,150,004...34,219,227
G
Utp11
UTP11, small subunit processome component
decreases expression
ISO
Piroxicam results in decreased expression of UTP11 mRNA
CTD
PMID:21858171
NCBI chr 5:136,931,279...136,946,164
Ensembl chr 5:136,931,008...136,946,191
G
Vcp
valosin-containing protein
decreases expression
ISO
Piroxicam results in decreased expression of VCP mRNA
CTD
PMID:21858171
NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571
G
Vdac3
voltage-dependent anion channel 3
decreases expression
ISO
Piroxicam results in decreased expression of VDAC3 mRNA
CTD
PMID:21858171
NCBI chr16:69,434,982...69,451,473
Ensembl chr16:69,435,005...69,451,471
G
Vegfa
vascular endothelial growth factor A
decreases expression
ISO
Piroxicam results in decreased expression of VEGFA mRNA
CTD
PMID:21858171
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
G
Vps28
VPS28 subunit of ESCRT-I
decreases expression
ISO
Piroxicam results in decreased expression of VPS28 mRNA
CTD
PMID:21858171
NCBI chr 7:108,341,989...108,345,837
Ensembl chr 7:108,341,989...108,345,837
G
Vrk1
VRK serine/threonine kinase 1
decreases expression
ISO
Piroxicam results in decreased expression of VRK1 mRNA
CTD
PMID:21858171
NCBI chr 6:124,914,770...124,981,508
Ensembl chr 6:124,914,855...124,981,436
G
Vrk2
VRK serine/threonine kinase 2
decreases expression
ISO
Piroxicam results in decreased expression of VRK2 mRNA
CTD
PMID:21858171
NCBI chr14:100,313,771...100,434,520
Ensembl chr14:100,313,601...100,434,527
G
Wars1
tryptophanyl-tRNA synthetase 1
decreases expression
ISO
Piroxicam results in decreased expression of WARS1 mRNA
CTD
PMID:21858171
NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
G
Xpc
XPC complex subunit, DNA damage recognition and repair factor
multiple interactions decreases expression
ISO
Cisplatin inhibits the reaction [Piroxicam results in decreased expression of XPC mRNA]
CTD
PMID:21858171
NCBI chr 4:123,993,670...124,020,922
Ensembl chr 4:123,993,666...124,021,010
G
Xpot
exportin for tRNA
decreases expression
ISO
Piroxicam results in decreased expression of XPOT mRNA
CTD
PMID:21858171
NCBI chr 7:57,111,536...57,152,013
Ensembl chr 7:57,111,536...57,152,099
G
Ybx3
Y box binding protein 3
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of YBX3 mRNA
CTD
PMID:21858171
NCBI chr 4:165,129,747...165,153,101
Ensembl chr 4:165,129,758...165,153,161
G
Ywhab
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta
increases expression
ISO
Piroxicam results in increased expression of YWHAB mRNA
CTD
PMID:21858171
NCBI chr 3:152,659,663...152,682,105
Ensembl chr 3:152,659,651...152,682,105
G
Zfp110
zinc finger protein 110
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in decreased expression of ZNF274 mRNA
CTD
PMID:21858171
NCBI chr 1:73,445,303...73,461,112
Ensembl chr 1:73,445,336...73,461,086
G
Zfp207
zinc finger protein 207
decreases expression
ISO
Piroxicam results in decreased expression of ZNF207 mRNA
CTD
PMID:21858171
NCBI chr10:65,385,807...65,398,086
Ensembl chr10:65,385,740...65,397,386
G
Zfp36l2
zinc finger protein 36, C3H type-like 2
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of ZFP36L2 mRNA
CTD
PMID:21858171
NCBI chr 6:10,490,032...10,494,073
Ensembl chr 6:10,490,032...10,494,064
G
Zmat3
zinc finger, matrin type 3
multiple interactions
ISO
[Piroxicam co-treated with Cisplatin] results in increased expression of ZMAT3 mRNA
CTD
PMID:21858171
NCBI chr 2:115,106,046...115,136,888
Ensembl chr 2:115,106,966...115,136,863
G
Zmpste24
zinc metallopeptidase STE24
decreases expression
ISO
Piroxicam results in decreased expression of ZMPSTE24 mRNA
CTD
PMID:21858171
NCBI chr 5:134,627,218...134,660,360
Ensembl chr 5:134,627,229...134,660,110
G
Zmynd8
zinc finger, MYND-type containing 8
decreases expression
ISO
Piroxicam results in decreased expression of ZMYND8 mRNA
CTD
PMID:21858171
NCBI chr 3:154,528,917...154,629,532
Ensembl chr 3:154,529,043...154,628,463
G
Zwilch
zwilch kinetochore protein
increases expression
ISO
Piroxicam results in increased expression of ZWILCH mRNA
CTD
PMID:21858171
NCBI chr 8:64,638,401...64,670,911
Ensembl chr 8:64,637,672...64,675,916
G
Zwint
ZW10 interacting kinetochore protein
decreases expression
ISO
Piroxicam results in decreased expression of ZWINT mRNA
CTD
PMID:21858171
NCBI chr20:15,938,157...15,953,997
Ensembl chr20:15,938,157...15,953,957
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all